Podcasts about Phase

Dein Zyklus verändert sich, du schläfst schlechter, bist gereizter, aber beim Arzt heißt es, dafür bist du noch zu jung. Willkommen in der Perimenopause, einer Phase, über die viel zu wenig gesprochen wird. In dieser Folge erkläre ich, was hormonell wirklich passiert, warum bioidentische Hormone niemals ohne vorherige Blutabnahme gestartet werden sollten, und welche Werte du dafür kennen musst.Was dich in dieser Folge erwartet:- Warum die Perimenopause ein hormonelles Auf und Ab ist, kein gleichmäßiges Absinken- Welche Symptome zu niedrigem und welche zu zeitweise erhöhtem Estradiol gehören- Warum bioidentische Hormone ohne Diagnostik ein Blindflug sind- Die zentralen Blutwerte und ihre Optimalbereiche, von Estradiol und Progesteron über SHBG bis Schilddrüse- Warum das Verhältnis zwischen den Werten mindestens so wichtig ist wie die Einzelwerte- Welche Lebensmittel mit Phytoöstrogenen dich in dieser Phase natürlich unterstützen könnenWenn du gerade merkst, dass du in dieser Phase steckst und Klarheit statt Blindflug haben möchtest, komm gerne in meine kostenlose, unverbindliche Sprechstunde:https://meetings.hubspot.com/makromanufaktur/youtube

Welcome to the Mind Muscle Connection Podcast!Calorie cycling can be a useful tool during both fat loss and building phases. In this episode, I break down how I use calorie cycling, including redistributing calories throughout the week, increasing or decreasing the weekly deficit, and using higher-calorie days around training.I also cover practical examples of how to set up calorie cycling during fat loss, when lower-calorie or protein-sparing modified fast days may make sense, and how I use calorie cycling in a building phase, including what I call a reverse refeed.So if you want to learn how to adjust your calorie intake throughout the week based on your goals, training, and recovery, this episode is for you.Let's talk about:Three Ways to Use Calorie Cycling During Fat LossRedistributing Calories Without Changing the Weekly Deficit + ExamplesProtein-Sparing Modified Fast DaysThe Trade-Offs of More Aggressive Calorie CyclingUsing Calorie Cycling to Change the DeficitIncreasing the Deficit With Lower-Calorie DaysUsing Maintenance Days to Reduce the DeficitHow I Typically Use Calorie Cycling With ClientsWhen to Increase the DeficitWhen to Decrease the DeficitChoosing the Right Size DeficitHow to Adjust Calorie Cycling Over TimeCalorie Cycling During a Building PhaseUsing Higher-Calorie Days Around TrainingWhere Calorie Cycling Can Go WrongHow to Set Up Higher and Lower DaysPractical Building Phase Calorie Cycling ExamplesAdjusting Calories as a Building Phase ProgressesThe Reverse RefeedWhy Use a Reverse Refeed?Who Should and Shouldn't Use a Reverse RefeedHow a Reverse Refeed Can Be MisusedHow to Set Up a Reverse RefeedLevels of Reverse Refeed + ExamplesBody Recomp Workshop Replay: https://chipper-producer-6244.kit.com/791129889cFollow me on Instagram for more information and education: https://www.instagram.com/jeffhoehn_/?hl=enHow You Can Work With Me?: https://jhhealth.net/workwithme/Coaching application: https://docs.google.com/forms/d/e/1FAIpQLSfE-99wLDZRXlOOY1pWuAmkogdZOm-7ZvN_thbqNWLdNrj5bg/viewform  

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic maneuvers shaping the landscape of drug development and patient care. Bayer's Kerendia, known generically as finerenone, has achieved its third FDA approval, this time targeting chronic kidney disease linked with type 1 diabetes. This small molecule mineralocorticoid receptor antagonist plays a critical role in mitigating fibrosis and inflammation—key factors in chronic kidney disease progression. Given the high prevalence of kidney complications in diabetic patients, this approval marks a significant step forward in managing such conditions. Its mechanism offers a novel approach to addressing cardiovascular and metabolic disorders, underscoring its vital role in contemporary therapeutic strategies. In regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu has secured approval from NICE for treating HER2-low breast cancer. This marks a significant transition toward precision medicine, allowing the NHS to provide more targeted cancer therapies. Enhertu, an antibody-drug conjugate, exemplifies the shift towards precision oncology by delivering cytotoxic agents directly to cancer cells expressing HER2, thus opening new avenues for personalized treatment strategies. Japan's MHLW has given the green light to GSK's Shingrix in prefilled syringe form for shingles prevention. As a recombinant zoster vaccine enhanced by an adjuvant system, Shingrix represents cutting-edge vaccine technology aimed at strengthening immune responses against the varicella-zoster virus. This approval not only broadens preventative measures but also highlights advancements in vaccine delivery systems. Novo Nordisk's collaboration with Orbis Medicines is another noteworthy development, focusing on oral macrocycle therapies for cardiometabolic conditions—a partnership with potential milestones valued at $1.4 billion. This move aligns with Novo Nordisk's strategic push into small molecule drug discovery to address unmet needs in cardiovascular and metabolic disorders, echoing a broader industry trend towards innovative therapeutic approaches. Meanwhile, Roche has ventured into an agreement with Dualitas Therapeutics to develop bispecific antibody platforms for autoimmune diseases. With an upfront payment of $36.5 million and potential milestone payments reaching $1 billion, this collaboration underscores the burgeoning interest in bispecific antibodies' capacity to target dual antigens simultaneously—offering promising new pathways for treating complex immunological conditions. On the clinical trial front, Roche's Lunsumio has met its Phase 3 primary endpoint, showcasing improved progression-free survival in patients with relapsed or refractory follicular lymphoma. This bispecific antibody exploits the immune system by targeting CD20 on B-cells while engaging CD3 on T-cells, highlighting its potential as an effective option for difficult-to-treat cancers. Conversely, Longeveron's laromestrocel faced setbacks in its Phase 2b trial for hypoplastic left heart syndrome—a reminder of the complexities inherent in developing cell therapies for cardiovascular diseases. Such challenges highlight the critical need for innovative approaches and continued perseverance within clinical development. Regulatory scrutiny remains a pertinent issue as evidenced by the FDA's warning letter to Bausch & Lomb over contamination concerns. This action emphasizes ongoing challenges within ophthalmology manufacturing standards and regulatory compliance—critical aspects that demand rigorous attention to ensure patient safety. These developments collectively reflect an industry characterized by dynamic scientific advancements and strategic collaborations aimed at addressing pressing health challenges through cutting-edge drug development and precision medicine. As companies continue to invest in innovative research and form strategic alliances, these efforts offer significant promise for improving patient outcomes through more effective and targeted therapies. The evolving regulatory landscapes and technological advancements will undoubtedly shape these trends further, offering new opportunities for growth and breakthroughs in patient care. The commitment to overcoming complex challenges remains at the forefront of industry priorities as stakeholders strive to deliver impactful treatments to patients worldwide. Thank you for tuning into Pharma Daily; stay with us as we continue to explore these transformative developments shaping the future of healthcare science.Support the show

Zum YouTube Video Manche Sätze treffen Dich derzeit so richtig - viel stärker, als sie vielleicht gemeint sind, und ein Streit kann sich plötzlich um etwas drehen, das Jahre zurückliegt. Dahinter steckt eine Wunde, die mit Deinem Selbstwert zutun hat, die Du schon seit 2018 mit Dir herumträgst und die am 10. September durch die Konstellation von Venus und Chiron wieder aufgebrochen ist. Dies war der Anfang einer Phase, die uns gerade emotional sehr mitnehmen kann. Und ein Ausweichen ist absolut zwecklos. Bis Ende des Monats September 2026 nähern sich genau dieser Wunde gleich mehrere Himmelskörper, einer nach dem anderen, und jeder stellt eine andere Frage. Langsam kann die tiefere Bedeutung der Verletzung ans Licht kommen. Intensiv aber mit großem Heilungspotenzial. Venus hat die Stelle am 10. September in Dein Bewusstsein gebracht. Mars drückt am 27. September ebenfalls besonders kraftvoll auf genau diesen Punkt, mit einem Konflikt oder einer klaren Grenze, aber noch ohne Erklärung. Erst Merkur schafft am 30. September genug Abstand, um zu begreifen, worum es wirklich geht. Dazwischen stellen Lilith und Sedna die Frage nach Selbstliebe und Verrat, und die Tag- und Nachtgleiche am 23. September legt Deinen Selbstwert und Deine Beziehungen auf eine gemeinsame Waage. Es ist wirklich emotional sehr viel los, in diesem September. Ich spreche in dieser Folge über: - Warum Deine Wunde von 2018 gerade jetzt so bedeutsam ist - Was Reibung und Streit mit Wachstum zu tun haben - Wofür sich ein Risiko in einer Beziehung lohnt und warum Du Dir mit Entscheidungen noch Zeit lassen darfst - Was Verrat und Selbstverrat miteinander verbindet - Warum Wahrnehmen in diesen Wochen vor dem Lösen kommt - Wie Du erkennst, welchen Anteil Du selbst an einem Muster hast, ohne Dir die Schuld zu geben - Eine Übung mit Stift und Papier für das Gleichgewicht zwischen Ich und Wir - Was der 27. und der 30. September in Deinem Alltag auslösen können Schau in Dein Chart und finde heraus, ob die Tore 3, 50, 10, 29, 30 oder 41 bei Dir aktiviert sind: https://human-design-system.com/human-design-chart-erstellen/ Ab 6. Oktober: Human Design Analytiker Training PTL I Meine Jahresgruppe für alle, die nach den Grundlagen in die analytische Tiefe gehen wollen. Human Design wird hier verkörpert unterrichtet. https://human-design-system.com/professional/ Ab 16. Oktober: Living Your Design Intensivkurs Der Einstiegskurs für alle, die Human Design gerade erst kennenlernen. https://human-design-system.com/living-your-design-seminar/ Mehr von der Human Design Academy: Website: https://human-design-system.com Instagram: @humandesign-academy Wenn Dir die Folge gefallen hat, freue ich mich über Deine Bewertung, einen Kommentar oder eine Weiterempfehlung an jemanden, der gerade merkt, dass ein altes Beziehungsthema wieder anklopft.

-Join Our Patreon And Over 50 Exclusive Episodes In 2026. All Episodes Ad-Free & Early Access https://www.patreon.com/cw/GeekVerse-Find Our Discord, Podcast/Video Feeds & Social Media In The Link Below! https://solo.to/geekverseMarvel BS Metre-Reportedly, Marvel is deciding whether to make the sequel to ‘The Punisher: One Last Kill' a series or a movie.-The alleged detective-themed special currently in production by Marvel Studios, if successful, could become a full series. This isn't the Jessica Jones/Luke Cage rumoured special.-Marvel Studios doesn't plan on putting Peter on the sideline post Miles Morales. It seems both Marvel Studios and Sony are interested in both of them having solo projects running at the same time.-In Phase 7, there will be a new Captain America alongside Sam Wilson-Red Skull returning in Phase 7- there will be a Captain America 5.-Dr. Strange is one of the leaders of the Midnight Suns film?-Valeria Richards will be in Secret Wars?-Marvel Studios will reportedly introduce Ka-Zar and the Savage Land in ‘BLACK PANTHER 3'TRAILERSInfirmary, Crystal Lake, Capturing Bigfoot, Other Mommy, Animals, Primetime, Mr. Irrelevant, Hunger Games Sunrise On The Reaping, Sacrifice, Christmas With The Kringles-What We've Been WatchingBecome a supporter of this podcast: https://www.spreaker.com/podcast/geekverse-podcast--4201268/support.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of dynamic and significant advancements across the industry, from strategic acquisitions to regulatory shifts and scientific innovations. In a bold move, Novartis has acquired Sironax's blood-brain barrier delivery platform for $125 million. This acquisition marks a strategic enhancement in Novartis's ability to deliver therapies directly to the brain, overcoming one of the most formidable challenges in treating neurological disorders. The potential to deliver antibodies and other therapeutic agents effectively across this barrier could lead to groundbreaking treatments for conditions like Alzheimer's disease and multiple sclerosis. This reflects a broader industry trend emphasizing improved drug delivery systems to boost treatment efficacy and patient outcomes. On the clinical advancement front, Sling Therapeutics has raised $123 million in a Series C funding round aimed at propelling its oral therapy for thyroid eye disease forward. Unlike traditional intravenous treatments, this oral therapy offers a more convenient option for patients, potentially improving adherence and quality of life. Meanwhile, Circle Pharma's $92.5 million Series E funding will support the development of its cyclin D1 inhibitor for breast cancer, showcasing innovation in oncology through the use of macrocycles that could provide more effective treatments with fewer side effects. Investments in AI and machine learning are also reshaping the landscape. Ginkgo Bioworks' collaboration with Novo Nordisk to construct an autonomous lab highlights the increasing role of automation in optimizing R&D productivity. Mithrl's $20 million Series A round further underscores this shift, focusing on developing an AI infrastructure platform for streamlined biopharma drug discovery processes. The regulatory environment continues to evolve with notable challenges. BioMarin has discontinued Phase 2 development of Voxzogo in Noonan syndrome due to shifting treatment landscapes, illustrating the dynamic nature of therapeutic development. Similarly, Novartis's halt on its TREM2 stabilizer after a Phase 2 failure in ALS research points to the complexities inherent in neurodegenerative disease studies. Maat Pharma faced a setback when its appeal was rejected regarding the EMA's negative opinion on its graft-versus-host disease candidate, Xervyteg. This instance highlights the stringent regulatory hurdles companies must navigate to bring novel therapies to market. Amid these developments, Gilead Sciences is strategically expanding into oncology and inflammation. Through several acquisitions, Gilead has diversified its portfolio significantly, emphasizing oncology as a central focus area given its high potential for addressing unmet needs and offering substantial returns on investment. Legend Biotech's appointment of Ingrid Zhang as CEO signals a strategic push into the competitive CAR-T cell therapy market. These therapies represent a revolutionary approach in personalized medicine for cancer treatment, with Legend positioning itself for growth and innovation. Bristol Myers Squibb and Ono Pharmaceutical are preparing to contest Amgen's efforts to launch a biosimilar for their oncology blockbuster Opdivo. This reflects broader competitive dynamics within the biologics market where biosimilars promise more cost-effective options, potentially reshaping market shares and pricing strategies. Manufacturing innovations are also at play with Ori Biotech securing a $120 million deal for an automated production platform in cell therapy manufacturing. Such advancements are crucial as cell therapies become more mainstream, necessitating scalable solutions that maintain quality while meeting demand. Operational expansions continue as Reckitt Benckiser allocates $600 million to upgrade its US operations, fostering innovation across health and hygiene product lines—an industry trend towards integrating R&D with manufacturing prowess to drive new product development. While challenges persist—illustrated by Novartis's multiple trial failures—the pharmaceutical and biotech sectors remain resilient with adaptive strategies focused on innovation. The ongoing advancements underscore not only scientific exploration but also strategic maneuvering amidst evolving regulatory landscapes. As AI reshapes talent acquisition strategies and technological advancements accelerate drug discovery processes, companies must navigate complex global health ecosystems poised for transformative growth. The focus remains on improving patient outcomes through cutting-edge science while balancing innovation with strategic realignment. Thank you for tuning into Pharma Daily—where we keep you abreast of pivotal industry shifts shaping the future of healthcare. Join us again tomorrow as we continue exploring these exciting developments impacting patient care worldwide.Support the show

Today the Captains Quadrant Joins with several other podcasters to be a part of the Trek Podcast Federation. Our goal here is to be present when and where our friends cannot! This past August started phase 1. Thanks to the Transporter Room and Letter Decks a card with a QR code was passed out to the fans at two scifi conventions and we were honored to have had 400 scans! In the manner of keeping it forward we will be doing whats called a bonus show on ALL of our platforms, A round table of different hosts from the various shows! An audio drama featuring three star trek actor from DS9 and Trek Continues, Phase 2... a spooky story time with former star trek actor Michael Chan, the back ground crew of Star Trek Voyager and Enterprise: Letter Decks. A quarky duo from the north of england, The Transporter Room and a pod that is Undiscovered... we join together with myself Joe Dove from the Captains Quadrant! https://linktr.ee/trekpodcastfederation

In this episode of Styling Matters, Lizzi shares her curated Phase Eight Autumn Winter 26 edit, highlighting the standout new-in pieces for the season. From polished workwear to Phase Eight's fabulous leather and suede collection, this is a collection defined by rich autumnal palettes, considered details and pieces designed to make getting dressed feel effortlessly stylish.Phase Eight is a brand Lizzi has recommended for years, season after season, for its ability to deliver investment-worthy style that works beyond the 9-to-5. In this edit, she talks through the pieces worth knowing about now — from smart separates and workwear staples to those standout autumn pieces that can earn their place in your wardrobe long after the working day is over.Follow Lizzi on Instagram at @lizzi.richardsonMore on Substack at https://stylingmatters.substack.com/Watch this episode on YouTube

In dieser Folge nehme ich dich mit in eine Phase, vor der ich selbst unglaublich großen Respekt hatte: das Wochenbett. Ich hatte viele Gedanken und Sorgen: Wie wird es sein, plötzlich nicht mehr zu arbeiten, keinen Sport zu machen, mit Schlafmangel und dieser enormen hormonellen Umstellung umzugehen – während sich gleichzeitig das ganze Leben verändert? Rückblickend kann ich sagen: Mein Wochenbett war viel schöner, als ich es erwartet hatte. Und ich glaube, dass meine bewusste Vorbereitung einen großen Anteil daran hatte.Du hörst, was in den ersten sechs bis acht Wochen nach der Geburt körperlich, hormonell, mental, emotional und seelisch passiert – und wie du dich auf diese besondere Zeit vorbereiten kannst, ohne zu erwarten, dass sich alles planen oder kontrollieren lässt.Wir schauen uns das Wochenbett entlang der vier ganzheitlichen Säulen an: Körper, Kopf, Emotionen und Seele. Dabei verbinde ich medizinisches Wissen mit meinen persönlichen Erfahrungen als frischgebackene Mama und gebe dir konkrete Impulse, die dir mehr Verständnis, Sicherheit und Selbstmitgefühl schenken können.Ab dem 21. September 2026 findest du hier den ausführlichen Blogartikel zur Folge.Du erfährst unter anderem:was bei Rückbildung und Wochenfluss im Körper passiert und welche Warnzeichen du ernst nehmen solltestwarum echte Ruhe im Wochenbett kein Luxus ist und wie ich Bewegung und Sport ganz langsam wieder aufgebaut habeweshalb ich einen Beckenboden-Check bei einer spezialisierten Physiotherapeutin jeder Frau empfehlen würdewas beim Milcheinschuss und Stillen passiert und welche Erfahrungen ich mit Stillvorbereitung und Mastitis gemacht habewie der starke Abfall von Östrogen und Progesteron deine Stimmung beeinflussen kannworan du den Unterschied zwischen Baby Blues und postpartaler Depression erkennst und wann du dir Unterstützung holen solltestwarum anhaltende Erschöpfung oder depressive Symptome nach der Geburt auch körperliche Ursachen wie eine Postpartum-Thyreoiditis haben könnenwie Schlafmangel und ein veränderter Cortisolrhythmus auf Stimmung, Energie und Nervensystem wirken – und was dir im Alltag helfen kannwarum Ernährung, Mikronährstoffe und konkrete Unterstützung durch Partner:in, Familie oder Freund:innen im Wochenbett so wertvoll sindwas der Begriff Matreszenz bedeutet und warum Liebe, Dankbarkeit, Frust und Trauer gleichzeitig da sein dürfenwie sich die Partnerschaft nach der Geburt verändert und was uns geholfen hat, miteinander verbunden zu bleibenwarum du keine Mutterrolle spielen musst, sondern dich selbst ganz neu als Mama entdecken darfstDas Wochenbett ist nicht einfach nur eine kleine Erholungspause nach der Geburt. Es ist eine medizinisch relevante Heilungsphase und gleichzeitig eine tiefgreifende Transformation. Du wirst Mama – aber du musst dich dabei nicht verlieren. Du darfst dich verändern und trotzdem kleine Stücke von dir selbst bewahren.Vielen Dank an den Sponsor dieser Episode: babyforte.deHat dir die Folge geholfen? Dann freue ich mich riesig, wenn du sie teilst und mir eine Bewertung bei Spotify oder Apple Podcasts dalässt – das ist das größte Geschenk, das du mir zurückgeben kannst.Charlotte ist approbierte Ärztin, Life Coach und staatlich geprüfte Ernährungsberaterin. Sie verbindet medizinisches Wissen mit Coaching-Tools aus NLP, EFT und Klinischer Hypnose – für ganzheitliche Gesundheit auf allen Ebenen.Für dich ⁠ausführlichen Blogartikel zur Folge.⁠Newsletter abonnieren: Impulse für ganzheitliche Gesundheit direkt in dein PostfachTermin für meine ärztliche Online-Sprechstunde: hier buchen1:1 Mentoring: Jetzt bewerbenInstagram: @dr.med.charlotte.schroerenHat dir diese Folge gefallen?⭐ Hinterlasse eine 5-Sterne-Bewertung auf Apple Podcasts oder Spotify.

Brayden reports the City's well pumps are back up and running, discusses ongoing projects, Phase 2 of Harlem, lead service line replacement, and more on the WRAM Morning Show.

Meine Biografie „UMWEGE – Mein Leben zwischen Rausch und Liebe“:⁠ https://umwege.sebastiancaspar.de John, 22 I Der Kokainkonsum eskaliert. Immer mehr, immer häufiger – und irgendwann kommt der Gedanke: Wenn ich so weitermache, sterbe ich.In dieser Folge erzählt mein Gast von einer Phase, in der Koks immer größere Teile seines Lebens bestimmt. Der Konsum wird exzessiver, die Kontrolle geht verloren und die körperlichen und psychischen Folgen lassen sich nicht mehr verdrängen.Wir sprechen über Suchtdruck, durchgemachte Nächte, Angst und den Moment, in dem klar wird, dass es so nicht weitergehen kann.Eine persönliche Geschichte über Kokain, Kontrollverlust und die Erkenntnis, dass der nächste Rausch irgendwann der eine zu viel sein könnte.

What if your DNA could give you an owner's manual for your health?In this fascinating episode of the Wise Divine Women Podcast, Dana Irvine welcomes Dr. Aaron Goldman of DNA Labs Canada to explore how genetic testing is helping shape the future of personalized health, nutrition, lifestyle, and medicine.Dr. Goldman shares how his background in molecular biology and genetics led him to create DNA Labs and explains how advances in genetic sequencing have made personalized DNA information increasingly accessible.Together, Dana and Dr. Goldman discuss how genetics can influence everything from the way we metabolize medications to nutrient requirements, food sensitivities, hormone metabolism, detoxification pathways, brain health, and long-term disease risk.One of the most important messages from this conversation is that genetic risk is not destiny. Your DNA sequence generally does not change, but understanding your genetic predispositions may help you make more informed decisions about food, lifestyle, testing, and prevention.Dr. Goldman also explains the difference between genetics and epigenetics—how lifestyle and environmental factors may influence the way certain genes are expressed.In This Episode, You'll Discover:

When was the last time a DM conversation you started actually turned into a sale, a recruit, or a real relationship?If you are sitting there thinking it has been a while, or honestly never, you are not alone. DM conversations are where most network marketing businesses live or die. And nobody really talks about why they fail.Until today

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant strides and strategic maneuvers reshaping the landscape of healthcare and drug development. Kicking things off, GlaxoSmithKline (GSK) has made headlines with its acquisition of Chimagen Biosciences' trispecific T cell engager technology, targeting multiple myeloma. This move, valued at up to $750 million, highlights GSK's strategic focus on expanding its oncology pipeline through cutting-edge immunotherapeutic approaches. Trispecific T cell engagers are an emerging class of biologics that bind to three different targets simultaneously, effectively arming the immune system to recognize and destroy cancer cells more efficiently. This acquisition not only strengthens GSK's position in the competitive oncology market but also addresses a significant need for more effective multiple myeloma treatments. In parallel, Curium has achieved a notable milestone with the FDA approval of Bexlutry, a radioligand therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This therapy utilizes radioactive isotopes attached to molecules that specifically target cancer cells, delivering radiation directly while minimizing harm to healthy tissue. The approval of Bexlutry is a crucial development in oncologic care, expanding treatment options for patients dealing with complex and heterogeneous tumors. It underscores the growing role of targeted radiotherapies in providing precision medicine solutions. On the financial front, Electra Therapeutics is gearing up for an initial public offering (IPO) to raise $325 million. The proceeds are intended to advance its late-stage clinical trials for severe hemophagocytic lymphohistiocytosis (SHLH), a rare autoimmune condition. This move reflects a broader trend among biotech companies turning to public markets to support niche therapeutic areas with high unmet needs and potential orphan drug status benefits. Turning to clinical advancements, Corbus Pharmaceuticals has reported encouraging Phase 1b data for CRB-913, which employs CB1 inverse agonism in combating obesity. By modulating endocannabinoid activity linked to appetite and energy balance, this approach offers a promising direction for managing metabolic disorders. Simultaneously, CSL Seqirus has shared Phase 3 results showcasing the superior efficacy of its MF59-adjuvanted cell-based quadrivalent influenza vaccine in older adults, highlighting ongoing innovations in vaccine technologies tailored for vulnerable populations. The FDA's regulatory landscape is also evolving with the launch of Operation Trialblazer. This initiative seeks to streamline early-phase U.S. clinical trials through expedited IND application processes, facilitating faster transitions from research to clinical applications and fostering innovation by reducing bureaucratic hurdles. Meanwhile, the FDA is preparing for potential psychedelic medicine approvals, ensuring robust oversight frameworks are in place as these therapies near market availability. Yet, as always in drug development, challenges persist. Novo Nordisk's decision to terminate its GLP-1 obesity drug partnership with Ascendis following unsatisfactory results exemplifies the inherent risks even promising preclinical data can present. Similarly, setbacks faced by Axoltis Pharma and Eli Lilly with their neurological and metabolic candidates reinforce the complexities of translating scientific hypotheses into viable therapies. Sanofi has taken significant strategic steps as well by divesting 20 older medicines and three manufacturing sites to Cheplapharm. This decision aligns with Sanofi's focus on innovation under CEO Paul Hudson's leadership and allows the company to reallocate resources towards groundbreaking therapies. In diagnostic advances, the FDA's approval of Telix's Pixclara marks a breakthrough for brain cancer imaging. Being the first FET-PET imaging drug approved for gliomas, Pixclara could significantly enhance diagnostic accuracy and treatment planning for these challenging tumors. These developments underscore a transformative period where scientific innovation is paired with strategic regulatory adjustments to navigate complex market dynamics. As companies continue adapting to these changes, their ability to innovate while addressing safety and efficacy concerns will be critical in advancing therapeutic frontiers and improving patient outcomes across diverse medical landscapes. As always, we'll be here at Pharma Daily to keep you informed on these pivotal changes shaping our industry's future. Thank you for tuning into today's episode of Pharma Daily. Keep innovating and stay informed!Support the show

Im ersten Teil des Podcasts sprechen Tim Deisinger und Ex-General Erhard Bühler über die aktuelle Lage an der Front. Nach Angaben von Bühler müssen die Russen weiterhin hohe Verluste hinnehmen. An einigen Stellen wurden sie zurückgedrängt. Besonders bei Lyman im Norden konnten die ukrainischen Truppen taktische Erfolge erzielen. Währenddessen haben die russischen Drohnenangriffe nach einer relativ ruhigen Phase wieder zugenommen. Moskau setzt verstärkt strahlgetriebene Drohnen ein, die von der ukrainischen Luftabwehr schwerer abzuschießen sind. Die ukrainischen Angriffe treffen vor allem russische Häfen, Kriegsschiffe und Raffinerien. US-Präsident Trump ist das ein Dorn im Auge, er befürchtet weiter steigende Ölpreise und übt Druck auf Kiew aus. Bühler sieht darin allerdings ein reines Ablenkungsmanöver. Es sei vor allem der Krieg gegen den Iran, der die Ölpreise und damit auch die Spritpreise in den USA in die Höhe treibe. Im zweiten Teil des Podcasts geht es um angeblich positive Signale aus Moskau. Nach der letzten Reise der US-Unterhändler Witkoff und Kushner soll Putin Verhandlungsbereitschaft signalisiert und einige Bedingungen fallen gelassen haben. Bühler bleibt skeptisch und spricht von "Scheinverhandlungen". Seiner Ansicht nach bleibt Putin bei seiner harten Haltung. Wenn Sie Fragen haben: Schreiben Sie an general@mdraktuell.de oder rufen Sie kostenfrei an unter 0800 637 37 37. Info: Die nächste Ausgabe von "Was tun, Herr General?" ist für den 17. September 2026 geplant.

BioVie CEO Cuong Do joined Steve Darling from Proactive to discuss what the company believes is a significant breakthrough in the treatment of long COVID, reporting that its lead drug candidate, Bezisterim, became the first therapy to demonstrate improvements across the three hallmark symptoms of the condition—fatigue, malaise and brain fog—in a well-controlled clinical trial. Do noted that the National Institutes of Health (NIH) RECOVER Initiative has supported eight clinical studies evaluating 13 different interventions for long COVID, yet none have demonstrated meaningful effectiveness to date. Against that backdrop, he said BioVie's results stand out as an important milestone in the search for therapies targeting the complex and often debilitating condition. According to Do, the trial delivered three major insights into long COVID and how it may be treated. First, the study confirmed that long COVID is highly heterogeneous, meaning patients experience symptoms very differently. Only about 15% of participants entered the study with severe levels of all three major symptoms, while roughly 20% were not significantly affected by any of them. Second, the data showed that patients must have a meaningful level of symptom severity at baseline in order to demonstrate measurable improvement. This finding may help guide future trial designs and patient selection strategies. Third, and most importantly, patients with a high symptom burden experienced clinically meaningful and statistically significant improvements. Participants suffering from severe fatigue saw improvements in fatigue-related measures, those with pronounced malaise experienced gains in both malaise and cognitive function, and patients with severe brain fog demonstrated measurable improvements in cognitive impairment endpoints. Looking ahead, Do said BioVie expects biomarker data from the study within the next several months. The company hopes those results will provide further insight into the biological mechanisms behind Bezisterim's effects and help validate the therapeutic approach. Following the biomarker analysis, BioVie plans to request an end-of-Phase 2 meeting with the U.S. Food and Drug Administration to discuss the design of a Phase 3 trial. The company is also pursuing grant funding opportunities to help support the next stage of development for its long COVID program. Beyond long COVID, BioVie continues to advance Bezisterim as a potential treatment for Parkinson's disease. Do said the company has been working closely with clinical experts to finalize the design of a registrational Phase 3 study and believes it has identified the appropriate endpoints, study size and duration needed to demonstrate the drug's potential to address both motor and non-motor symptoms of Parkinson's. He added that Bezisterim could potentially become the first therapy capable of not only improving symptoms but also modifying disease progression. BioVie expects to receive formal FDA feedback on its Phase 3 Parkinson's trial design before the end of the year. proactiveinvestors #biovieince #nasdaq #bivi #Bezisterim #LongCOVID #Healthcare #Biotech #ClinicalTrials #BrainFog #Fatigue #MedicalResearch #ParkinsonsDisease #DrugDevelopment #FDA #Biotechnology #LifeSciences #HealthcareInnovation

IP Group PLC (LSE:IPO) CEO Greg Smith spoke with Proactive's Stephen Gunnion about a strong start to 2026, with NAV per share reaching around 117p and cash proceeds topping £85 million year to date. Smith discussed progress in Pfizer's obesity programmes, including the berobenatide and amylin combination moving into Phase 2b, alongside further positive data from Pfizer's lead Phase 3 programme. He also highlighted the wider portfolio, with companies raising more than £540 million of third-party capital in the first half across areas including quantum computing, AI, healthtech and cleantech. IP Group has now generated more than £150 million of realisations since the start of 2025 towards its £250 million target by the end of 2027. Smith also discussed the group's expanding private capital platform and the potential catalysts across the portfolio over the next 12 to 18 months. Visit Proactive's YouTube channel for more interviews and market updates. If you found this video useful, give it a like, subscribe to the channel and enable notifications for future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #IPGroup #IPGroupPLC #GregSmith #InterimResults #Investing #UKInvesting #TechnologyInvesting #DeepTech #HealthTech #CleanTech #QuantumComputing #ArtificialIntelligence #AIInfrastructure #Pfizer #ObesityTreatment #OxfordQuantumCircuits #QuantumMotion #Oxa #PortfolioCompanies #GrowthInvesting #ProactiveInvestors #Proactive

Diese Folge ist für dich, wenn du verstehen möchtest, warum du in manchen Wochen fokussiert und voller Energie bist und in anderen erschöpft und gereizt – und wie du dieses Wissen für deine Produktivität nutzen kannst. In manchen Wochen läuft einfach alles wie am Schnürchen. Du bist fokussiert, kreativ, voller Energie. Und dann gibt es diese Phasen, in denen du dich fragst, warum du plötzlich erschöpft bist, langsamer wirst und gereizter reagierst. Das hat oft mehr mit deinem Zyklus zu tun, als du denkst. In dieser Folge spricht Birgit Amelung mit Mandy Jochmann, Expertin für zyklusorientiertes Arbeiten, darüber, wie wir mit unserem Zyklus statt gegen ihn arbeiten können – und warum das nicht nur unsere Produktivität, sondern auch unsere Gesundheit nachhaltig verändern kann.   Außerdem in dieser Folge: • Warum zyklusorientiertes Arbeiten kein Wellbeing-Trend, sondern eine Form der Selbstführung ist • Die vier Zyklusphasen und ihre jeweiligen Superkräfte • Warum die Periode nicht nur eine Rückzugsphase, sondern eine Phase von Weisheit und Klarheit ist • Wie zyklusorientiertes Arbeiten auch gelingt, wenn du deinen Kalender nicht frei gestalten kannst • Was PMS-Symptome uns eigentlich sagen wollen • Birgits vier Hacks für eine energiebewusste Wochen- und Monatsplanung • Warum Energie- statt Zeitmanagement der eigentliche Gamechanger ist • Und warum Prävention langfristig wichtiger ist als Krankheitstage   WERBUNG: HER KLUB EVENTS – DON'T MISS! 14. Oktober 2026 – mkk - meine krankenkasse X The HER KLUB Berlin – PRÄVOLUTION NIGHT! HIER TICKET SICHERN! ABOUT HER HEALTHY HUSTLE HER HEALTHY HUSTLE ist der Gesundheits-meets-Business Podcast von THE HER KLUB für alle, die viel leisten und ihre Gesundheit nicht länger hinten anstellen wollen. Ich bin Birgit Amelung, Gründerin von THE HER KLUB und der Agentur AWAKE, zweifache Unternehmerin, Mama von zwei Kindern, Buchautorin und Health-Enthusiastin. Ich habe selbst viele Jahre gehustled, bis mein Körper die Reißleine gezogen hat. Heute weiß ich: Gesundheit ist kein Nice-to-have, sondern die Grundlage für alles. In HER HEALTHY HUSTLE teile ich gemeinsam mit starken Expert:innen und inspirierenden Role Models fundierte Insights, ehrliche Erfahrungen und konkrete Health Hacks, die du direkt in deinen Alltag integrieren kannst. Jeden Mittwoch als Deep Dive oder snackable Strong Bite. KAPITEL (0:00) Intro – Zyklusorientiertes Arbeiten als Produktivitäts-Hack: Worum es in der Folge geht (1:42) Hustle: Birgits eigene Zykluserfahrung nach dem Mallorca-Umzug & ihre 4 Hacks für Wochen- und Monatsplanung (15:28) Health: Mandy Jochmann erklärt die 4 Zyklusphasen und ihre Superkräfte (38:16) Wie zyklusorientiertes Arbeiten auch ohne volle Selbstbestimmung gelingt (47:52) Was PMS & Zyklusbeschwerden uns eigentlich sagen wollen (49:52) Bester Health Hack: Radikal die eigenen Bedürfnisse ernst nehmen KLUB NEWS – KOSTENLOS HER KLUB MEMBER WERDEN INSTAGRAM  LINKEDIN

hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan spoke with Proactive's Stephen Gunnion about the company's results for the first half of 2026, its record order book, full-year guidance and the expansion of its clinical research services. Khan said hVIVO generated around £16.3 million in revenue in H1, alongside an EBITDA loss of £4.5 million, ending the period with £13 million in cash, a performance in line with the company's previous guidance that 2026 would be weighted towards the second half. A key focus was the order book. Three sizeable human challenge trial contracts, including hVIVO's first pivotal Phase 3 trial with ILiAD, took it to £65 million at the end of June, rising to £72 million including CRS Berlin, acquired in Q3. "This is the highest record order book in the company's history," Khan said, noting it was calculated using a stricter, more conservative methodology and provides visibility into the rest of 2026 as well as 2027 and 2028. For the full year, hVIVO expects second-half revenue to almost double versus H1, targeting £47 million and a low single-digit EBITDA loss, with the company expecting to turn EBITDA positive during H2. Khan also discussed hVIVO's evolution beyond its core human challenge trial business into a more integrated CRO offering spanning consulting, laboratory services and non-human challenge Phase 1 and 2 trials, with the acquisitions of CRS Mannheim, Kiel and Berlin adding capacity and therapeutic expertise, including dermatology and women's health. Watch the full interview to hear more about hVIVO's outlook and strategy. Visit Proactive's YouTube channel for more videos, and don't forget to like the video, subscribe to the channel and enable notifications for future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #hVIVO #HVO #ClinicalTrials #ClinicalResearch #CRO #HumanChallengeTrials #Biotech #Biotechnology #Pharma #DrugDevelopment #Phase1 #Phase2 #Phase3 #LifeSciences #Investing #AIMStocks #ProactiveInvestors

Coyote Copper Mines CEO Daniel Weir joined Steve Darling from Proactive to discuss a major advancement at the company's wholly owned Copper Springs Project, announcing that Coyote has received full approval for its Phase 1 drilling permits following the successful completion of its Plan of Operations. The approval represents an important milestone for the company as it moves from exploration and target generation into an active drilling phase aimed at unlocking the project's copper potential. Weir explained that regulators have authorized a total of 37 drill locations across the Copper Springs Project. Each location can accommodate multiple drill holes, providing the company with significant flexibility as it evaluates a range of priority targets. Under the permit terms, Coyote has three years to complete all drilling and reclamation activities associated with the approved program. The upcoming Phase 1 drilling campaign will target both near-surface oxide copper mineralization and deeper sulphide copper systems, giving the company an opportunity to test multiple styles of mineralization across the project area. These targets were developed through extensive exploration work that included geological mapping, surface sampling, and several generations of geophysical surveys designed to identify and prioritize prospective zones. To further enhance drill targeting, Coyote is continuing additional fieldwork that includes soil sampling, channel sampling and new geophysical surveys. The company believes the ongoing work will help refine target locations and maximize the effectiveness of the Phase 1 drill campaign. At the same time, management is already planning for the project's next stage of exploration. Weir confirmed that preparations for Phase 2 drilling permits will begin shortly, demonstrating the company's commitment to advancing Copper Springs through a systematic and multi-year exploration strategy. In another significant development, Coyote has expanded its land position around the project by staking 111 additional mineral claims, increasing the overall footprint of the Copper Springs Project to approximately 72.36 square kilometres. The company is also progressing a new 2D Induced Polarization (IP) geophysical survey, a key component of its exploration program. Phase 1 of the survey is currently underway and covers approximately 17 line kilometres across survey lines L1 through L7 in the central-eastern portion of the property. The survey is expected to be completed by mid-September. #proactiveinvestors #coyotecoppermines #tsxv #ccmm #CopperSprings #CopperMining #CopperExploration #MiningNews #CriticalMinerals #JuniorMining #DrillProgram #Geophysics #InducedPolarization #MineralExploration #ResourceStocks #CopperStocks #ProactiveInvestors #SteveDarling

Everyone experiences the release phase during rebalancing but not everyone notices it happening.As harmful bacteria, yeast, mold, fungus, parasites, heavy metals, toxins, and waste are cleared, the body has to process and eliminate what is being released. Some women and children notice temporary changes in energy, digestion, poop, sleep, skin, mood, or the symptoms they are healing. Others move through the release phase without feeling or seeing anything unusual at all.In this episode, Juniper explains what the release phase actually is, why it's a beautiful and necessary part of healing, and why noticeable discomfort is not proof that the ōNLē Rebalance Method is working, or not.You will also learn why preparation matters, how drainage and elimination support the body's ability to release, and why Cleanse, Nourish, Bind, and Remineralize work together as one complete methodology.Your body is not fighting you. It's finally letting go of what it no longer needs to carry.Thanks for listening! I can't wait for you to experience the ōNLē transformation. ♡Subscribe to the Nourished NewsletterExplore the Gut Rebalance KitsVisit our FAQ'sFollow along on a InstagramTake the free Gut Health QuizEmail us at customercare@onleorganics.comSending love and wellness from my family yours,xx - Juniper BennettFounder of ōNLē ORGANICS

If you've spent years trying to move with a "flat back" or bracing your core like you're about to be punched, you've likely noticed that it doesn't really reduce your pain. If anything you are just getting tighter and more uncomfortable. Conventional fitness advice tells us to stabilize and stiffen to protect our spines, but modern pain science reveals a different reality.Your nervous system has likely forgotten how to let go of the "emergency brake," a phenomenon known as sensory motor amnesia. In this episode, we move from the theory of last week into a clear, evidence-based roadmap for teaching your body that it is safe to be supple, mobile, and strong again.What You'll Discover:The Flexion Relaxation Paradox: Why healthy spines actually "shut off" their muscles when bending forward, while pained backs stay stuck in a hyper-vigilant electrical fire.The Ischemia of Bracing: How white-knuckle core clenching chokes off blood supply to your tissues, triggering the very pain you're trying to avoid.The 12-Week Roadmap: A look at the 4 distinct phases—from floor-based somatics to progressive resistance—required to rebuild a body that can lift groceries or barbells without fear.Referenced Science:Van Dieen, J. H., et al. (2019). "Trunk muscle recruitment patterns in patients with low back pain." PubMedGeisser, M. E., et al. (2005). "A meta-analytic review of surface electromyography among persons with low back pain and normal, healthy controls." PubMedKarayannis, N. V., et al. (2013). "Fear of movement is related to trunk stiffness in low back pain." PubMedStep-by-Step Somatic Strength:Try the Somatic Strength Collective App (7-Day Free Trial)Free Fear Avoidance Self-Assessment:Free Move Beyond Pain RoadmapBook a Strategy Session with Mandy: Timestamps[00:00] - Intro: Dismantling the Bracing Myth.[03:38] - The "Emergency Brake" Habit.[06:33] - Research: The Stiffening Strategy.[07:44] - The Flexion Relaxation Phenomenon.[15:52] - Understanding Sensory Motor Amnesia.[20:53] - The Danger of OSHA Advice.[24:21] - Phase 1: Calming the System.[28:40] - Phase 2: Floor-Based Somatics.[31:30] - Phase 3: Graded Standing Exposure.[34:58] - Phase 4: Progressive Tissue Resilience.[45:08] - Reclaiming a Liberated Life.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into some of the latest breakthroughs, regulatory updates, and strategic maneuvers reshaping the landscape of drug development and patient care. Starting with remarkable advancements in drug approvals, Scholar Rock's Isembldy (apitegromab), a monoclonal antibody designed to inhibit myostatin, has secured FDA approval for treating spinal muscular atrophy. This approval came after successful Phase 3 trials and marks a significant milestone in managing neuromuscular diseases. By targeting the myostatin pathway, which regulates muscle growth, Isembldy offers hope for improved motor function in patients suffering from this debilitating condition. Meanwhile, Pharming's Joenja (leniolisib) received an expanded label from the FDA, now approved for pediatric patients aged four and older with activated phosphoinositide 3-kinase delta syndrome, reflecting ongoing efforts to tackle rare autoimmune disorders. Telix Pharmaceuticals has also made strides with the approval of Pixclara (floretyrosine F 18) for PET imaging of glioma, enhancing diagnostic precision for both adult and pediatric brain cancer patients. In clinical trial successes and challenges, GSK and Hansoh Pharmaceutical reported that their antibody-drug conjugate, risvutatug rezetecan, significantly reduced the risk of death in Phase 3 trials for relapsed small-cell lung cancer by 54%. This underscores the potential of targeted therapies in oncology, especially where second-line treatments have been limited. AstraZeneca's Tagrisso (osimertinib), meanwhile, continued to demonstrate its efficacy with a notable reduction in death risk in early-stage EGFR-mutated non-small cell lung cancer at an eight-year follow-up, reinforcing its value as an adjuvant therapy. However, AstraZeneca faced setbacks with camizestrant's Phase 3 trial failing to meet primary endpoints in estrogen receptor-positive breast cancer. A similar challenge arose with Enhertu (trastuzumab deruxtecan) in HER2-mutant non-small cell lung cancer, indicating ongoing difficulties in developing effective combination therapies. Turning to strategic business developments, Johnson & Johnson's decision to divest its orthopedics unit DePuy Synthes to Apollo Equity Management for $20 billion reflects a strategic refocus on core areas like pharmaceuticals and medical devices. Similarly, Novo Nordisk's rebranding as 'Novo' signals an effort to strengthen its competitive stance against Eli Lilly within the GLP-1 agonist market, crucial for managing metabolic disorders such as diabetes. In collaborations and licensing deals aimed at broadening access to healthcare innovations, Bio Usawa's partnership with Axmed is set to enhance access to affordable biologic medicines across Africa, a vital step towards expanding healthcare reach in underserved regions. In oncology research advancements, Owkin has licensed its AI-driven K Pro scientist platform to Servier to accelerate drug discovery through artificial intelligence and machine learning applications. Regulatory challenges continue to shape industry dynamics. The FDA has postponed its decision on Exelixis's Zanzalintinib combined with Roche's Tecentriq for metastatic colorectal cancer until March 2027, reflecting rigorous scrutiny to ensure safety and efficacy. Meanwhile, Cellectis has opted to halt its allogeneic CAR-T programs amid increasing competition from in vivo approaches, showcasing strategic adaptability within the rapidly evolving field of cell therapy. In recent news focusing on mRNA technology and personalized cancer vaccines, Moderna's flu vaccine approval using mRNA technology marks a pivotal moment for this platform after facing skepticism over the years. Furthermore, Moderna and Merck have reported positive Phase 3 results for their personalized mRNA-based cancer vaccine—an advancement positioning them as leaders in personalized cancer immunotherapy following success in melanoma treatment. The sector remains dynamic as companies navigate these complex environments. Breakthroughs such as ivonescimab's success provide optimism for future innovations that could significantly enhance patient care and treatment outcomes across various diseases. The emphasis on mRNA technologies and personalized medicine heralds a new era of targeted therapies poised to redefine standards of care across multiple disease areas. As these initiatives progress, they hold potential not only for improving existing treatment paradigms but also for pioneering new frontiers in healthcare delivery. As these developments unfold, they highlight the industry's dual focus on advancing scientific innovation while navigating complex regulatory landscapes and competitive pressures. The implications are profound: promising enhanced patient outcomes through novel therapies while prompting strategic realignments among key industry players. These initiatives not only aim to improve existing treatment paradigms but also pioneer new frontiers in healthcare delivery.Support the show

Most ergonomists follow a similar path. School, where the theory is fascinating but the practical is thin. Learning the ropes, where the real work begins and the gap between what you studied and what clients actually need becomes very clear. And then the big question: is entrepreneurship the final boss?This episode maps the three phases of the ergonomics career journey through an honest, experience-based lens, covering what school gives you and what it doesn't, the three paths into real-world ergonomics experience, and what the shift toward independent practice actually requires, starting with the thing most ergonomics programs never teach: marketing.What's covered:Phase 1: School, what ergonomics education gives you and the critical gap between theory and practiceWhy office ergonomics assessments specifically are the practical gateway to everything else in the fieldPhase 2: Learning the ropes, the three paths (internship, mentorship, nine-to-five) and when each one makes sensePhase 3: Flying your wings, what the entrepreneurship decision actually looks like and how to approach itWhy job security in a nine-to-five is more of an illusion than it feelsThe marketing system problem: why scattered posts don't build a practiceThe real question: are you known as the go-to ergonomics professional in your city, or invisible until someone gets hurt?Free live training for new ergonomists: ergonomicshelp.com/ergo-webinarScale your ergonomics practice with Accelerate: ergonomicshelp.com/accelerateOn September 23rd join this free live training and learn the exact system ergonomists are using to build their list, get referred more, and stop undercharging for work that deserves more.  https://ergonomicshelp.com/infographic/

On this week's episode, Tess Cameron, Brian Skorney, Paul Matteis, and Yaron Werber open with a look at markets, noting the XBI slipped just over 3% amid concerns about energy prices, inflation, and long-term U.S. fiscal health weighing on the rate-sensitive sector. The conversation then turns to policy, discussing new FDA leadership appointments including Karim Mikhail as CBER director, with hosts noting the industry's hope for a calmer, less chaotic regulatory tone. They highlight the FDA's apparent openness to psychedelics, pointing to stock reactions across the space. On the data front, Novartis's pelacarsen missed expectations reducing Lp(a) relative to rival programs from Amgen and Eli Lilly, while its DM1 program also fell short, shifting attention to Dyne Therapeutics' upcoming expansion cohort data. The hosts debate whether Novartis's setbacks make early-commercial, post-Phase 3 companies more attractive acquisition targets given looming loss-of-exclusivity pressure across large pharma. In other data news, Roivant's mosliciguat hit its Phase 2 primary endpoints in interstitial lung disease, with the company already advancing to Phase 3. The episode closes with Biohaven's epilepsy trial hold pending further metabolite data, and questions over whether the hold could affect its recent SK Pharma deal. This episode aired on September 11, 2026.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Michael Davidson is a world-renowned cardiologist, lipidologist, and the founding CEO of NewAmsterdam Pharma. He begins this episode by sharing how his family history shaped his interest in lipidology and primary prevention. He explains why prevention should focus on causal drivers of disease rather than near-term risk and examines the causal relationship between LDL and atherosclerotic cardiovascular disease. Michael then traces the complicated history of CETP inhibitors—from the original rationale that raising HDL would reduce cardiovascular risk to the failures of torcetrapib, dalcetrapib, and evacetrapib—and explains how lessons from these trials ultimately led to the development of obicetrapib. He reviews the phase 2 and phase 3 trials of obicetrapib, its effects on LDL-C, apoB, LDL particle number, and Lp(a), the ongoing cardiovascular outcomes trial, and where the drug could fit alongside statins and other lipid-lowering therapies. Peter and Michael discuss the relationship between statins and diabetes risk, then turn to the potential role of obicetrapib in Alzheimer's disease prevention, exploring the genetics of APOE4 and CETP, cholesterol metabolism within the brain, and emerging biomarker data. Finally, Peter and Michael explore the benefits of omega-3 fatty acids and the challenge of delivering DHA to the brain, as well as ongoing work on klotho in preparation for clinical trials. They discuss the potential for AI to transform clinical trials and the scientific and financial challenges of developing new therapies for cardiovascular and neurodegenerative disease. We discuss: Michael's path to lipidology, and his passion for primary prevention [3:30]; Reframing prevention around causal drivers rather than time horizon [9:30]; What CETP inhibition does, the evolutionary biology of CETP, the HDL-raising rationale, and Pfizer's torcetrapib failure [15:00]; Why raising HDL is thought to be beneficial, a quick review of the functions of HDL, and how this connects to torcetrapib [24:00]; The graveyard of CETP inhibitors: Roche's dalcetrapib, Lilly's evacetrapib, and Merck's REVEAL trial [27:15]; The causality of LDL in cardiovascular disease [34:30]; Reviving obicetrapib at NewAmsterdam, and confirming the benefit is LDL lowering: the TULIP data, the abandoned statin-intolerance path, and the Mendelian randomization verdict on HDL [37:30]; Phase 2 and phase 3 trials of obicetrapib—ROSE, BROOKLYN, BROADWAY, and TANDEM—and the PREVAIL outcomes trial, with the European and US approval paths [44:45]; Discordance among LDL-C, LDL-P, and apoB with CETP inhibition, and obicetrapib's Lp(a)-lowering effect [50:30]; Where obicetrapib fits in the lipid-lowering toolkit, the case against high-dose statins, and the problem of drug pricing [57:30]; The case for obicetrapib in Alzheimer's: the APOE4 and CETP genetics, the animal models, and funding Alzheimer's research [1:03:45]; Brain cholesterol metabolism and the APOE4 mechanism: the blood-brain barrier, astrocyte cholesterol efflux, the amyloid-tau cascade, the role of HDL, and why statins don't cause Alzheimer's disease [1:08:00]; The biomarker evidence: the CSF pilot study, Alzheimer's as a disease of middle age, the pharma graveyard problem, and the p-tau 217 results from BROADWAY [1:17:45]; Whether obicetrapib translates into clinical benefit for Alzheimer's disease: the risk of fooling yourself, the persistence of the amyloid dogma, ARIA in APOE4 homozygotes, and the next prevention trial [1:28:00]; Fish oil, EPA, and DHA: the cardiovascular trials and the challenge of delivering DHA to the brain [1:32:00]; Two open problems: using AI to reform clinical trials, and the statin–diabetes signal [1:41:15]; What it takes to develop a drug, the biotech investment landscape, and the klotho program [1:48:15]; Closing reflections: what to do if you carry APOE4, balancing motivation against over-testing, and the need for multiple therapies [1:55:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

In this episode Andrea Samadi explains the concept of sleep stress — a wearable-device measured how physiologically activated your body remains during sleep — and places it within a neuroscience-based movement and recovery framework. She reviews the autonomic nervous system (sympathetic vs. parasympathetic), how WHOOP estimates sleep stress from heart rate and HRV, and why trends over weeks matter more than single nights. Using her six-month data, Andrea shares how recovery habits and removing alcohol coincided with an 89% drop in nightly high sleep stress. The episode ends with practical steps and a seven-day experiment to help you observe and reduce nighttime physiological activation by changing daytime behaviors, sleep environment, and training timing so your body can better recover and adapt. When Sleep Isn't Rest—What “Sleep Stress” Reveals About Recovery: The Story Behind My 89% Drop in Sleep Stress Welcome back to the Neuroscience Meets Social and Emotional Learning Podcast, where we bridge neuroscience, social and emotional learning, and human performance so we can create measurable improvements in our well-being, achievement, leadership, productivity and results. I'm Andrea Samadi, and if you've been following along through Season 16, you'll know that we have been building what I call The Brain's Operating System for Human Performance—a neuroscience-based framework designed to help us understand how the different systems of the brain and body work together to influence how we learn, adapt, connect, lead and ultimately perform. We are currently in Phase 3: Movement, Learning and Cognition, where we have been following a central pathway: Movement → Adaptation → Performance Movement creates a stimulus. But movement alone does not make the brain or body stronger. We must be able to recover from that stimulus before adaptation can occur, to give us our desired outcome of improved performance. This is why our recent bonus episodes have moved beyond exercise itself and into the recovery signals that help us understand whether our bodies are successfully handling the demands we are placing upon them. In Bonus Episode 3[i], we explored the hidden story behind my resting heart rate. My data showed that it was not merely a measure of fitness—it was also reflecting the total load my body was carrying. During the higher-stress months of January and February, my resting heart rate remained elevated at approximately 56–58 beats per minute. As I placed greater emphasis on sleep, hydration, Zone 2 movement, sauna, meditation and recovery, it gradually fell to 54 and then 53 beats per minute. The lesson was that a lower resting heart rate signals that the body is working less during rest, and recovering more efficiently. The idea is to learn what your baseline is, and see how you can improve this number for a more efficient RHR. In Bonus Episode 4[ii], we explored restorative sleep and learned that sleep quality is not measured by duration alone. Deep sleep supports physical restoration and repair, while REM sleep plays an important role in memory, learning and emotional processing. Because longer REM periods tend to occur later in the night/morning time my regular 4:00 AM wake time may give me less opportunity for that REM-rich portion of sleep—which is the tradeoff I'm choosing--since waking early allows me to exercise. Two additional hours in bed would not guarantee two more hours of REM, but they could create a greater opportunity for more REM sleep. The lesson was not to choose sleep over movement or movement over sleep. It was to protect enough sleep while still making room for movement, so the brain and body have the opportunity to adapt. Throughout these bonus episodes, I'm sharing patterns from my WHOOP wearable device[iii] data—not because everyone's numbers should look like mine, but to demonstrate what can happen when we measure consistently, look for trends and test small changes. The goal is not comparison. It is to help each of us better understand our own baseline and use that information to improve our habits, recovery and results. While examining my own sleep data for these recent bonus episodes, another question came to my mind. It was while looking this sleep stress score. What if we are sleeping—but our physiology remains unusually activated throughout the night? How would we even know if this was happening? This is another measurement I can see with this wearable device. What if our eyes are closed and we are technically asleep, but the body is still working harder than usual? What if our sleep isn't giving us the rest and recovery that we need. This brings us to today's question: What is Sleep Stress? One of the most valuable metrics I have been tracking this year is not simply how long I sleep or how much deep and REM sleep I achieve. Those are all important to me, but something stood out with these sleep scores to me, this year. It is the amount of time my body spends in a state of elevated physiological stress while I am asleep. When I examined my most recent six-month trend, I noticed something that kind of stopped me in my tracks. My average time in WHOOP's high sleep-stress zone (monthly score from January 2026 till now) initially rose from 21 minutes to a peak of 35 minutes (around April/May) where I noticed my sleep scores were terrible with International travel, but I can't blame everything on just the travel and times zones. I knew I was off track with rest and recovery. How much I was off, I'm not sure because Whoop confirmed my scores with the times zones might have been inaccurate, but either way, even if my sleep stress peaked at let's say 25 minutes, it still showed me that I was doing something to keep my body stressed out while I was sleeping. As I paid attention to rest and recovery, the scores began to improve in May, June, July, August…until now. 35 minutes of high sleep stress went…to 18…to 14…to 5…and finally to just 4 minutes of sleep stress each night. That is an approximately 89% decrease from my six-month peak. The data cannot tell me that one specific behavior caused this change. But it does suggest that my body has become progressively less physiologically activated while I was asleep. And this helped me see recovery in a new way. Sleep duration tells us how long we slept. Sleep stages estimate the type of sleep we experienced throughout the night. Sleep stress gives us another window into how physiologically activated the body remained during that sleep. In today's BONUS EP 5 we will explore: What Sleep Stress measures The sympathetic and parasympathetic branches of the nervous system Where Sleep Stress fits into the Movement Loop What I noticed in my six-month results What the results show—and what they cannot prove How you can monitor nighttime physiological stress And practical tips to help your body settle and recover Let's begin with the nervous system and what's working behind the scenes while we are asleep. The Autonomic Nervous System To understand Sleep Stress, we first need to understand the autonomic nervous system and how ACTIVATION and RECOVERY work together. We covered this topic on a very early EP 59[iv] with Suzanne Gundersen on “Putting the Polyvagal Theory into Practice” and then again with educational neuroscientist Dr. Lori Desautels and Michael McKnight[v]. You can review those episodes if you want a deeper dive here. The autonomic NS is the part of the nervous system that regulates many of the functions that happen automatically, without requiring conscious thought. It helps manage: Heart rate Blood pressure Breathing Digestion Temperature regulation Energy use And our physiological responses to changing demands in our life experiences Two of its primary branches are the sympathetic nervous system and the parasympathetic nervous system. The sympathetic nervous system helps mobilize the brain and body when we need energy, alertness or action. It is often called the fight-or-flight system. We need this sympathetic activation to wake up, exercise, concentrate, solve problems, respond to challenges and perform under pressure. When sympathetic activity rises, heart rate may increase, breathing may become faster and energy becomes more readily available for action. That is exactly what we want when climbing a mountain, completing an intense workout, delivering a presentation or responding to an immediate challenge. The problem is not activation itself. The problem may arise when the body has difficulty shifting out of that activated state after the challenge has passed. The parasympathetic nervous system supports the restorative side of this process. It is often described as the rest-and-digest system because it helps the body conserve energy, digest food and create conditions that support rest and recovery. When our parasympathetic NS is activated, heart rate generally slows and the body becomes less physiologically activated. But the sympathetic and parasympathetic systems are not simple on-and-off switches. They continually interact throughout the day and night. Healthy regulation depends on our ability to move flexibly between activation and recovery as our life circumstances change. I'm sure you've heard people talking about how they “regulate” themselves, or take themselves from a high stress state, to lower stress state usually through intentional breathing, (I've just started to add this technique), physical movement (my go-to way to get back to myself when I have time) and some people use sensory grounding to get themselves out of anxious loops. American neuroscientist Dr. Andrew Huberman suggests the physiological sigh as a breathing technique “to reduce stress and anxiety in real-time, while they are still engaging in life.”[vi] He does say that this pattern of breathing is something that we all engage in when we are in deep sleep (our dogs do it too), a double inhale, followed by an extended exhale. He says it works well to reduce stress because “it offloads a lot of carbon dioxide all at once.” Until I started to look at this sleep stress number, I didn't realize that even during healthy sleep, our autonomic activity fluctuates. Deep sleep is generally associated with greater parasympathetic influence, while REM sleep can include more variable heart rate, breathing and sympathetic activity. This means that brief periods of increased physiological stress during sleep are not automatically signs that something is wrong. The more useful question is: Can my body move flexibly between activation and recovery—or is it remaining unusually activated for extended periods? What Does WHOOP Mean by Sleep Stress? WHOOP estimates physiological stress using signals that include heart rate and heart-rate variability, or HRV, compared with your personal baseline. Its Sleep Stress view shows the proportion of the night spent in low, medium and high physiological stress zones. This is an important distinction: A wearable does not directly measure your thoughts or emotions. It cannot know whether you are worried, excited, digesting a late meal, fighting an infection or recovering from a difficult workout. It also does not directly measure the sympathetic and parasympathetic branches of the nervous system. Instead, it uses cardiovascular signals to estimate how physiologically activated your body appears relative to what is normal for you. Elevated nighttime stress can potentially be influenced by: Mental or emotional strain Alcohol Illness or an emerging infection A late or heavy meal Intense exercise close to bedtime Accumulated training strain Dehydration Heat or an uncomfortable sleep environment Travel and disrupted routines Hormonal changes Certain medications Or sleep-disordered breathing Sleep Stress should therefore be treated as a signal to investigate, not a diagnosis. One elevated night may not mean very much. The greatest value comes from observing your own patterns across several weeks and comparing those patterns with your behaviors, environment, training and health. Where Sleep Stress Fits in the Movement Loop Our original Phase 3 framework was: Movement → Adaptation → Performance But we can now expand this pathway: Movement → Physiological Load → Recovery → Adaptation → Performance Movement provides a challenge to the brain and body. That challenge creates physiological load. Recovery gives the body an opportunity to respond to the load, repair what was challenged and build additional capacity. That process is adaptation. And the capacity created through adaptation supports future performance. Sleep Stress sits within the recovery stage of this loop. It helps us investigate whether the body is successfully downshifting from the demands of the day or remaining more activated than usual during the recovery window. This does not mean that every increase in nighttime stress prevents adaptation. The body is dynamic. Exercise, digestion, illness, temperature and different stages of sleep can all affect nighttime physiology. But if elevated Sleep Stress becomes a repeated pattern, it may indicate that the body is carrying more load than it is currently absorbing. This is why Sleep Stress belongs in Phase 3: Movement supplies the challenge. Recovery determines how effectively we absorb it. Adaptation builds capacity. And capacity supports performance. What My Six-Month Results Show When I examined my 6-month Sleep Stress results from March 17 through September 12 when I was writing this episode, I first looked at six consecutive monthly windows: March 17–April 15: 21 minutes of average high Sleep Stress April 16–May 15: 35 minutes May 16–June 14: 18 minutes June 15–July 14: 14 minutes July 15–August 13: 5 minutes August 14–September 12: 4 minutes The pattern was not a straight decline. My average high Sleep Stress initially increased from 21 to 35 minutes. That April-to-May period (with International Travel) was the highest point in the six-month window—a 67% increase from the preceding month. The nightly graphs also show more frequent and more substantial periods in WHOOP's high-stress zone during that time. The data cannot tell me exactly what caused the increase. It may have reflected accumulated emotional stress, training load, disrupted routines, sleep timing, travel, temperature, or several factors interacting at once. But after that 35-minute peak, the direction changed: 35 → 18 → 14 → 5 → 4 minutes That is an approximately 89% reduction from the peak. This was not the result of one isolated night or a single unusually good week. It was a progressive decline across four consecutive monthly windows. When I switched to WHOOP's full six-month view, however, I initially noticed what appeared to be a contradiction. My six-month average was 16 minutes in the high-stress zone—60% higher than my preceding six-month average of 10 minutes. How could my current Sleep Stress be improving so dramatically while the six-month comparison still showed an increase? The answer is that a six-month average is a lagging measure. You can see my 6 month data in the show notes. This graph includes the elevated spring period, particularly the April-to-May peak of 35 minutes. Those earlier nights continue to pull the six-month average upward, even though my more recent results are much lower. The percentage of each night spent in WHOOP's different stress zones makes the recent change especially clear. During the April-to-May peak: 6% of my sleep was in the high-stress zone 27% was in the medium-stress zone 67% was in the low-stress zone By August 14 through September 12: High-stress sleep had fallen to 1% Medium-stress sleep had fallen to 10% Low-stress sleep had risen to 89% This may be the most meaningful finding in the entire six-month trend. I did not simply spend less time in WHOOP's high-stress zone. A much larger proportion of my night shifted into the low-stress zone. From spring into early summer, my high Sleep Stress had already begun to decline as I was focused on my health routine it kept dropping—from 35 minutes to 18 and then 14 minutes. I was living my life as usual. Three observations help explain what I think this pattern means. Observation One The Spring Peak Was Worth Investigating The 35-minute average represented a 67% increase from the preceding monthly window. The nightly graphs also show more frequent and more substantial periods in WHOOP's high-stress zone during that time. Something was placing a greater physiological demand on my system, but the screenshots cannot tell me precisely what it was. The increase could have reflected emotional stress, training load, disrupted routines, sleep timing, travel, illness, temperature or several factors interacting at once. This is why wearable data becomes more useful when it is paired with context. The number shows us what changed. A behavior log helps us investigate why it may have changed. Observation Two The Improvement Began Before August My Sleep Stress did not suddenly improve in one week. After the April-to-May peak, it declined across four consecutive monthly windows: 35 minutes fell to 18, then 14, then 5 and finally 4 minutes. That suggests an ongoing recovery shift rather than one isolated good night. By the latest monthly window, 89% of my sleep appeared in WHOOP's low-stress zone, compared with 67% during the spring peak. My body appeared to be spending progressively more of the night in a lower state of physiological activation relative to my baseline. Observation Three One Change May Have Strengthened the Trend Then, on August 7, I changed one thing. My movement, training, sauna, hydration and sleep practices remained relatively consistent. The clearest variable I intentionally changed was this: I stopped drinking alcohol. The timing matters. My July 15-August 13 average, which contained only the first week of the alcohol-free experiment, was already down to 5 minutes. Because most of that monthly window occurred before August 7, alcohol removal cannot explain the entire decline. But after I removed alcohol, my Sleep Stress remained at its lowest level and fell again to 4 minutes. During the same period, my HRV increased, my resting heart rate decreased and my overall recovery improved. These measures are related rather than completely independent-WHOOP's Stress Monitor itself uses patterns in heart rate and HRV. Still, when several parts of my recovery picture begin telling a consistent story after one clearly defined change, the pattern becomes more compelling. The data does not prove that removing alcohol caused every improvement. The most responsible conclusion is that my recovery had already begun improving and alcohol removal may have helped reinforce and sustain that progress. My Biggest Aha Moment My biggest realization was this: I was not improving my sleep only by changing what I did at night-such as cooling the room, using a sleep mask or limiting phone use before bed. I was improving my nights by changing my days. This is exactly what Dr. Kristen Holmes suggested we do on EP 4054. Everything we do during the day contributes to the total load our bodies must process: The emotional stress we carry The timing and intensity of exercise The food we eat The time we eat it Alcohol Hydration Light exposure Travel Work demands And whether we create moments of recovery between those demands The night can become a physiological reflection of everything that came before it. For years, many of us have assumed that being exhausted guarantees a good night's sleep. But exhaustion and regulation are not the same thing. We can be deeply tired and still physiologically activated. The goal is not to exhaust the body until it shuts down. The goal is to help the body transition from meeting the demands of the day into the conditions required for recovery. How Can YOU Measure Nighttime Stress? WHOOP provides a specific Sleep Stress view, but you do not need WHOOP to begin observing your recovery patterns. Depending on the wearable or device you use, you may be able to track: Sleeping heart rate Resting heart rate Overnight HRV Respiratory rate Skin-temperature deviation Sleep disruptions Restlessness Blood-oxygen trends And recovery or readiness scores The most important consideration is your personal baseline. Your HRV, resting heart rate and respiratory rate should not be judged against someone else's ideal number. Begin by learning what is normal for you. Then look for: Sudden deviations Repeated elevations Changes lasting several nights Connections with specific behaviors (I noticed that sleep stress was ALWAYS there after no more than 1-2 glasses of wine) And whether multiple measures change together (I noticed that after a long hike, if I chose to have a drink that night, even one glass of wine, sleep stress would be there the next day). There was no escaping what elevated it for me. Even without a wearable, you can begin tracking subjective signs of recovery. Each morning, ask: How many times did I awaken? Did I feel restored when I woke up? Was my mind calm or racing before bed? Did I wake with tension, a racing heart or unusual warmth? How was my energy, mood and focus the following day? You can then compare those observations with factors such as: Alcohol Meal timing Exercise timing Emotional stress Illness Travel And changes in your sleep environment The purpose is not to become anxious about every fluctuation. The purpose is to find patterns that help you make better decisions. It did help me to have a wearable to notice just how consistent my sleep stress was with certain behaviors. Can you measure Sleep Stress without a wearable? Not in the same way. Without overnight heart-rate and HRV data, we cannot calculate WHOOP's Sleep Stress score—and we may not consciously feel that our physiology remained activated. That was true for me. I did not feel stressed while I was sleeping. I needed the data to show me that my body was experiencing something my conscious mind could not detect. Without a wearable, we can still watch for indirect clues: repeated awakenings, morning fatigue, an elevated morning pulse, daytime sleepiness or a bed partner noticing snoring, gasping or restlessness. A sleep diary can help connect those clues with our daytime behaviors. The wearable did not create the stress. It made an invisible physiological pattern visible. How Can We Lower Sleep Stress? There is no single method guaranteed to lower nighttime stress because the underlying cause may differ from one person to another. The following ideas are best approached as individual experiments. Examine Alcohol Alcohol can make us feel sleepy, but sedation is not the same as restorative sleep. Try reducing or removing alcohol for several weeks and observe what happens to your Sleep Stress, HRV, resting heart rate, awakenings and morning energy. Look for a trend rather than expecting every night to improve. This isn't the first time I've removed alcohol while creating certain conditions for my body to perform at its best over the past 7 years of this podcast, and prior. I remember first hearing Dr. Daniel Amen talking about how alcohol isn't a health food, and that he suggests no amount to be healthy for the brain. When I first heard him say this, I did think, “Oh come on, Dr. Amen, say it's not so” because I don't eat junk food (we'll cover this topic next) so I would almost look to find some research that would allow even just small amounts. You can hear what Dr. Huberman[vii] suggests on his riveting episode on this topic, and I'm sharing that my reduction with sleep stress was significant enough for me to decide that cutting it out of my diet would be a permanent decision. This is a personal decision though and what might be significant for me with my results, might not be what you notice. Finish Eating Earlier A large or heavy meal close to bedtime may keep the body active through digestion. Experiment with finishing dinner earlier and leaving a consistent interval before sleep. Then observe whether your nighttime heart rate, Sleep Stress or restlessness changes. I've always had dinner around 5pm and don't eat anything after 6:30pm (except the occasional hot chocolate). Create an Evening Wind Down The brain and body need a transition between daytime demands and sleep. Your off-ramp might include: Dimming the lights Reducing stimulating content Reading Meditation Slow breathing NSDR Gentle stretching A warm shower or bath Writing down tomorrow's priorities Or following a consistent bedtime routine The purpose is to give the nervous system repeated cues that the demands of the day are ending. I like an Epsom salt bath when I'm home to transition from a work day, to night time. Balance Training With Recovery Exercise generally supports sleep and long-term health, but timing and intensity can affect individuals differently. If you repeatedly notice elevated nighttime stress after late, intense workouts, experiment with completing those sessions earlier. You might replace a late high-intensity session with walking, gentle mobility or recovery work and then compare the results. I did notice that on days I go to the gym after work, I do have higher stress that next morning. It's not always easy to fit everything in early mornings. Practice Regulation During the Day Do not wait until bedtime to address accumulated activation. Small recovery periods throughout the day can include: Brief movement breaks Time outdoors Slow breathing Space between meetings Short periods without digital stimulation Meditation Recovery does not begin when your head hits the pillow. It is built into the rhythm of the entire day. Optimize the Sleep Environment Examine the physical conditions surrounding your sleep: Is the room comfortably cool? Is it dark? Is it quiet? Are notifications turned off? Are pets or other interruptions waking you? Does your bedding help regulate temperature? Has travel disrupted your routine? Sometimes the source of elevated nighttime activation is due to your environment. Pay Attention to Possible Health Signals A sudden increase in nighttime stress—especially when accompanied by changes in resting heart rate, respiratory rate or skin temperature—may occur when the body is fighting an illness. Persistent changes deserve attention, particularly if they are accompanied by loud snoring, gasping during sleep, chest symptoms, unusual shortness of breath or significant daytime sleepiness. A wearable cannot diagnose sleep apnea, an infection or another medical condition. Its role is to help us notice when something has changed and decide whether further evaluation may be appropriate. A Seven-Day Sleep Stress Experiment This week, select only one or two variables to change. Your experiment does not have to involve alcohol like mine did. I honestly just stopped enjoying it, so it was an easy variable for me to pick. Don't ask me to give up coffee though. I won't be participating in any caffeine reduction experiments. Choose one variable that may be influencing your nighttime physiology, keep everything else as consistent as possible, and watch the trend—not one isolated score. You might: Avoid alcohol Finish dinner earlier Move intense exercise away from bedtime Create a 20-minute evening wind down routine Practice five minutes of slow breathing Or make the bedroom cooler and darker Each morning, record: Time in high Sleep Stress, if available HRV Resting heart rate Respiratory rate Number of awakenings And how restored you feel on a scale from 1 to 10 At the end of the week, ask: What changed? What remained consistent? Which behaviors appeared to help my body settle? Which behaviors were followed by greater nighttime activation? Do not try to produce a perfect score. The goal is to identify a pattern you can repeat. Review and Conclusion To close out this BONUS EP4, where we explored Sleep Stress—not as another score to chase, but as a window into what the body may be experiencing while we sleep. We learned that Sleep Stress estimates how physiologically activated the body remains during the night. It is different from sleep duration, which tells us how long we slept, and sleep stages, which estimate the kinds of sleep we experienced. To understand this metric, we looked at the two primary branches of the autonomic nervous system. The sympathetic nervous system mobilizes energy so we can move, focus, respond and perform. The parasympathetic nervous system supports conservation, digestion, restoration and recovery. Neither branch is inherently good or bad. We need activation to meet life's demands, and we need the ability to downshift when those demands have passed. Healthy regulation is not the absence of stress. It is the flexibility to move between activation and recovery. We also learned that WHOOP does not directly measure either branch of the autonomic nervous system. It uses patterns in heart rate and heart-rate variability, compared with our personal baseline, to estimate physiological stress. That makes Sleep Stress a useful signal—but not a diagnosis and not proof of what caused a particular change. This metric fits within the recovery stage of our expanded Movement Loop: Movement → Physiological Load → Recovery → Adaptation → Performance Movement creates the challenge. But the challenge alone does not build greater capacity. The body must be able to absorb the load, recover from it and adapt. When I examined my own six-month results, I saw my average high Sleep Stress rise from 21 minutes to a spring peak of 35 minutes. It then declined across four consecutive monthly windows: 35 → 18 → 14 → 5 → 4 minutes That represented approximately 89% reduction from the highest month The proportion of my sleep in WHOOP's low-stress zone also increased from 67% during the spring peak to 89% in my most recent monthly window. My recovery had already begun improving before I had cut out alcohol on August 7, so alcohol removal cannot explain the entire decline. But when I kept the rest of my routine relatively consistent and removed alcohol, my Sleep Stress remained at its lowest level. At the same time, my HRV increased, my resting heart rate decreased and my overall recovery improved. This does not prove that one behavior caused every change. But it gives me good reason to believe that removing alcohol helped reinforce an already improving recovery pattern. And that brings me to the most important lesson from this experiment: I did not improve my recovery by asking my body to do more. I improved it by creating better conditions for my body to recover from everything it was already doing. So tonight, instead of asking only: “How many hours will I sleep?” Think about-- “What am I doing today that will help—or prevent—my body from settling tonight?” Because the night does not begin when we close our eyes. It carries the accumulated effects of how we moved, trained, ate, worked, regulated and recovered throughout the day. Movement creates the stimulus. Recovery allows us to absorb it. Adaptation builds our capacity. And greater capacity prepares the brain and body to perform tomorrow. I'll see you next time for Episode 407, where we will revisit Jason Wittrock's work through a current and carefully defined lens. We'll examine his experience with nutrition and fasting as the perspective of an applied practitioner and personal case study, while comparing those ideas with current evidence surrounding nutrition, blood-sugar stability, metabolic flexibility, recovery and performance. Because if recovery determines how well we adapt to a challenge, metabolism determines whether the brain and body have the energy required to power that adaptation. And the brain and body cannot sustain performance without the energy required to power the system. I'll see you next time. REFERENCES: [i]Neuroscience Meets Social and Emotional Learning Podcast BONUS EP 3 https://andreasamadi.podbean.com/e/the-hidden-story-behind-your-resting-heart-rate/   [ii]Neuroscience Meets Social and Emotional Learning Podcast BONUS EP 4 https://andreasamadi.podbean.com/e/is-your-4-am-hike-costing-you-rem-the-movement-vs-sleep-trade%e2%80%91off/   [iii] whoop.com   [iv]Neuroscience Meets Social and Emotional Learning Podcast EP 59  https://andreasamadi.podbean.com/e/suzanne-gundersen-on-the-polyvagal-theory-in-practice/   [v]Neuroscience Meets Social and Emotional Learning Podcast “The Future of Educational Neuroscience”  https://andreasamadi.podbean.com/e/lori-desautels-and-michael-mcknight-on-the-future-of-educational-neuroscience-in-our-schools-and-communities/   [vi] Dr. Andrew Huberman Breathing Techniques to Reduce Stress and Anxiety. The Physiological Sigh https://www.youtube.com/watch?v=kSZKIupBUuc   [vii] Dr. Andrew Huberman https://www.hubermanlab.com/subtopics/effects-of-alcohol-on-the-brain-and-body  

In this episode of The PDB Situation Report:• The Iran conflict enters a new phase of escalation, and Behnam Ben Taleblu of the Foundation for Defense of Democracies joins us to explain what the latest developments mean and where the fight could go next.• On the 25th anniversary of the 9/11 attacks, we examine reports that the Pentagon is considering a smaller U.S. military footprint in the Middle East once the war with Iran ends, with Steve Yates of the Heritage Foundation joining us to discuss the potential implications.To listen to the show ad-free, become a premium member of The President's Daily Brief by visiting https://PDBPremium.com.Please remember to subscribe if you enjoyed this episode of The President's Daily Brief. YouTube: youtube.com/@presidentsdailybriefQUO: Make this the season where no opportunity slips away. Try QUO for free PLUS get 20% off your first 6 months when you go to https://Quo.com/PDBMOD: For a free consultation and get 10% off your first order PLUS free shipping with promo code PDB at https://mod.com

Friday, September 11, 2026 — Week 37 CAMP4 — ASCEND EXPANDS TO THE UK UK MHRA authorizes UK sites in CAMP4's Phase 1/2 CMP-002 trial. UK joins Australia + Argentina. EU filing remains under review. First-in-human trial still targeted to begin Q4 2026. Another major step toward our first disease-modifying clinical trial. https://investors.camp4tx.com/news-releases/news-release-details/camp4-therapeutics-receives-authorization-united-kingdom-phase CAMP4 ANALYST DAY — SEPT. 28 12–1:30 PM ET. Trial design + unmet need + early pipeline. CURE SYNGAP1 participating https://investors.camp4tx.com/news-events/events We will have a day after, webinar, stay tuned for details. USA TODAY — SYNGAP1 IN PRINT SYNGAP1 family story appeared in USA TODAY's national print edition this week. Families need education, care + support TODAY. https://www.usatoday.com/story/life/health-wellness/2026/09/01/kids-special-education-school-shortage-care/90851980007/ RARE-X + CITIZEN HEALTH Global Genes selects Citizen Health technology to power RARE-X. Important for us: ProMMiS uses Rare-X; CURE SYNGAP1 already works with Citizen. https://www.prnewswire.com/news-releases/global-genes-partners-with-citizen-health-to-power-rare-x-302870871.html SIX THINGS U.S. FAMILIES CAN DO Our Take Action page is LIVE. Don't just read it. Keep coming back until you've done all six. https://curesyngap1.org/TakeAction IEP HELP — CITIZEN HEALTH Oct. 4: IEP deep dive + Q&A with Staci Zimmerman, M.Ed. Register https://curesyngap1.org/calendar/what-nobody-tells-you-about-ieps-citizen-health-webinar/ RESEARCH — HELP WANTED 2-year SYNGAP1 postdoc — Sapienza University of Rome. Patient iPSCs, cortical neurons + brain organoids. Deadline Sept. 30. Know someone? Amplify it. https://www.sins.it/job_offer/postdoctoral-position-available-at-sapienza-university-of-rome/  COMMUNITY QUICK HITS NEW WARRIOR: Felipe, age 3. Parents Brian + Alana organizing Fight for Felipe. Want to fundraise? New support form: https://cureSYNGAP1.org/Fundraise Café SYNGAP1 #40 + #41: GRIN2A + GRIN2B communities. https://cureSYNGAP1.org/Cafe Night of Impact recap live. Time to start planning the next one. https://cureSYNGAP1.org/SF26Recap UPCOMING EVENTS — COUNTDOWN SHOOT FOR SYNGAP1 — 64 DAYS November 14 — Hurricane, Utah Aiming for a Cure — Shooting for Hope https://cureSYNGAP1.org/Shoot FIGHT FOR FELIPE — 78 DAYS November 28 — Boston, Massachusetts https://cureSYNGAP1.org/Fight CURE SYNGAP1 CONFERENCE — 83 DAYS December 3–4 — Denver, Colorado https://cureSYNGAP1.org/Reg26 USA

Program notes:0:33 Vaccines for RSV, flu, and Covid1:35 Studies available right now2:33 Reduction of hospital encounters for infants3:33 Maternal vaccination for RSV4:34 Gene silencing therapy for cardiomyopathy5:35 Decreased primary outcome about 20%6:35 Should we be screening?7:06 A new protein to pinpoint preeclampsia8:05 Low levels in first trimester9:08 Anchors embryo to uterus10:05 A new therapy for COPD exacerbations11:05 Phase three trial of monoclonal12:34 End

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant advancements and challenges that are shaping the future of drug development, regulatory landscapes, and industry innovations. Starting with a major milestone in personalized cancer therapy, the FDA has expanded Bayer's approval for Hyrnuo (zipalertinib) to include its use as a first-line treatment for HER2-mutant non-small cell lung cancer (NSCLC). This approval is based on promising Phase 1/2 clinical data, highlighting zipalertinib's role as a tyrosine kinase inhibitor targeting specific genetic mutations. This development is part of a broader trend towards precision medicine in oncology, allowing treatments to be specifically tailored to patients' genetic profiles. The potential impact on patient care is substantial, offering more effective treatment options for those with this particular HER2 mutation. In parallel, Johnson & Johnson's Imbruvica (ibrutinib) regimen has been endorsed by NICE for mantle cell lymphoma. These advancements represent a significant shift towards integrating precision medicine into oncology, aiming to improve outcomes by focusing on individual patient needs. On the business front, Samsung Biologics has secured a $262 million manufacturing deal with an unnamed European pharmaceutical company. This highlights an increasing demand for biologics manufacturing capabilities and reflects a growing reliance on contract development and manufacturing organizations (CDMOs) to meet complex therapeutic needs. Meanwhile, EMD Serono's acquisition of PostEra's AI-discovered fertility programs marks a pivotal move towards incorporating artificial intelligence in drug discovery, potentially revolutionizing women's health and fertility treatments. Clinical trial successes continue to drive momentum in the sector. AbbVie's Qulipta (atogepant) achieved its primary endpoint in a Phase 3 trial focused on menstrual migraines through CGRP receptor antagonism. This positions Qulipta as a promising new therapy within neurological disorders. Similarly, Rezera's Ruvonoflast met its primary endpoint in treating peripheral artery disease via NLRP3 inhibition, showcasing innovative anti-inflammatory approaches within cardiovascular medicine. Investment remains robust across the industry landscape. Frazier Life Sciences has successfully raised $1.1 billion to support small to mid-cap biotech companies, aiming to foster innovation and support emerging firms through critical phases of drug development. Additionally, CordenPharma's €80 million investment in enhancing aseptic fill-finish capacity illustrates strategic expansions within pharmaceutical manufacturing infrastructure. However, regulatory challenges persist. NICE's rejection of Gilead Sciences' lenacapavir due to cost concerns underscores ongoing debates around drug pricing and accessibility within healthcare systems. Furthermore, Biohaven Pharmaceuticals faces a partial clinical hold by the FDA on its epilepsy drug trial due to safety concerns. These instances highlight the rigorous scrutiny required throughout drug development processes. In response to these challenges, companies are increasingly adopting sophisticated strategies to navigate the evolving regulatory landscape. The "most favored nation" pricing policy in the U.S., designed to align domestic drug prices with those abroad, is prompting pharmaceutical firms to reassess their market strategies amid shifting economic conditions. On an optimistic note, Encoded Therapeutics has raised $275 million in Series F financing aimed at advancing gene therapies for conditions like Dravet syndrome. This substantial investment underscores confidence in gene therapy as a transformative approach for treating complex neurological and rare diseases. Finally, Ionis Pharmaceuticals achieved a breakthrough with its therapy approval for Alexander disease, illustrating the growing emphasis on targeting genetic disorders through precision medicine approaches. Such developments reflect both the dynamic nature of scientific innovation and the inherent challenges that accompany it. As these advancements unfold across various therapeutic areas and technological innovations continue to transform industry practices, it becomes increasingly clear that strategic planning and investment in research are crucial for translating scientific breakthroughs into tangible patient benefits. The ability of companies to innovate while ensuring compliance and economic viability will be pivotal as they strive to redefine treatment paradigms within this highly competitive sector. Thank you for joining us today on Pharma Daily. Stay tuned for more updates as we continue to bring you the latest insights from the ever-evolving pharmaceutical and biotech industries.Support the show

It's time for our annual Conference League league phase preview! We begin by going through our power rankings and identifying the primary contenders in the tournament. We explain why we think Brighton, Monaco, and Freiburg are a cut above the rest and why Atalanta has a lot of work to do. We also identify some of our favorite teams outside of the top echelon, including Copenhagen and Frankfurt, and some teams that have a lot to prove, like Trabzonspor. We move on to some of our favorites mixtures through the six match days, including blockbuster matchups between contenders, and discuss the hardest and easiest schedules. We also select some of our favorite upset candidates who could surprise. Next, we draft our top contenders to make the top 8 in the final table, thus securing the all-important bye to the round of 16, and finish the episode with another edition of New Fun Kids To Watch (In A Sporting & Not Creepy Way). Which Conference League youngsters are destined for stardom? Cheers to everyone (who's morally deserving)! Chapters: 00:00 – the start 24:52 – betting favorites 26:29 – fixtures, hardest + easiest schedules 33:14 – top 8 draft 40:48 – youngsters to watch

At COP26 in Glasgow, India famously asked to change one word in the final text. ‘Phase out' became ‘phase down'. The COP President fought back tears, as country after country branded this a moment of shame. For many, India has been a villain of that story ever since.But like all stories about this country, the truth is far more complex.In the last of three episodes from India, Tom Rivett-Carnac asks what the world gets right and wrong about the pivotal role that India is playing on the global climate stage. And Christiana Figueres returns to the microphone to trace the argument India has been making in every negotiating room for three decades - and where it might go next.We meet Ambassador Manjeev Singh Puri, who was at Copenhagen in 2009, when the rich world promised billions of climate finance to the developing world. But much of that money never came, and what did arrive came mostly as debt. He has a theory about why India still doesn't get the credit he believes it deserves, and it has nothing to do with the climate.Harjeet Singh, who has campaigned on this for twenty years, shares why his own government treats coal as a matter of national security rather than energy policy.And Dia Mirza tells us what she did when the Chief Justice of India called people like her a ‘lobby'.So is India the blocker, or the blueprint? And what happens to the rules when the countries that wrote them stop keeping them?Learn More

https://www.universetoday.com/articles/7-stage-journey-reveals-how-falling-space-rocks-survive-air By Laurence Tognetti, MSc - August 31, 2026. Recorded by our Editor, Richard Drumm. At least once in our lives, we've all seen a bright streak of light briefly blaze across the sky and have quickly referred to it as an asteroid, meteor, shooting star, comet, or some other whimsical name we've heard others use to describe it. For those calling it a meteor, you would be correct, but we'll touch upon this later. The time it takes for a space rock, bolide being its scientific name, to travel through Earth's atmosphere and crash into the ground literally takes only a few seconds. But what happens to a space rock during this very brief travel time, and how can scientists use this to learn about a specific space rock's origin and the potential damage it could cause if it explodes in mid-air?   Phase 1: Atmospheric entry;  Phase 2: Brightness begins;  Phase 3: Brightness increases with fireball appearance;  Phase 4: Brightness maintains while melting begins;  Phase 5: Front of rock begins to break apart;  Phase 6: Back of rock breaks apart;  Phase 7: Melting and breaking apart continue until glowing stops, followed by melting ending and wind discards crusted pieces. [Editor's Note: OK, that could be 8 stages if you'd prefer…]   We've added a new way to donate to 365 Days of Astronomy to support editing, hosting, and production costs.  Just visit: https://www.patreon.com/365DaysOfAstronomy and donate as much as you can! Share the podcast with your friends and send the Patreon link to them too!  Every bit helps! Thank you! ------------------------------------ Do go visit http://www.redbubble.com/people/CosmoQuestX/shop for cool Astronomy Cast and CosmoQuest t-shirts, coffee mugs and other awesomeness! http://cosmoquest.org/Donate This show is made possible through your donations.  Thank you! (Haven't donated? It's not too late! Just click!) ------------------------------------ The 365 Days of Astronomy Podcast is produced by the Planetary Science Institute. http://www.psi.edu Visit us on the web at 365DaysOfAstronomy.org or email us at info@365DaysOfAstronomy.org.

Donate now to Support Alzheimer's Research for Brighter Futures

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Sandoz's recent move to invest $2.5 billion in creating a vertically integrated biosimilar manufacturing network is making waves across the industry. This significant investment underscores the growing importance of biosimilars as cost-effective alternatives to biologics. With plans to develop 100 biosimilars by 2040, Sandoz is strategically positioning itself to meet increasing global demand for affordable treatments. This initiative not only enhances their production capabilities but also aligns with the push from healthcare systems worldwide for more economical care options. The vertical integration model promises to streamline production, reduce supply chain issues, and maintain high-quality standards, reinforcing Sandoz's competitive position in the biosimilars market. Meanwhile, Amgen has achieved a noteworthy milestone with its drug Imdelltra (tarlatamab-dlle), which met its Phase 3 overall survival endpoint for extensive-stage small-cell lung cancer (SCLC) maintenance therapy. Imdelltra, a bispecific T-cell engager targeting DLL3, represents a novel approach in oncology, potentially setting a new standard of care for SCLC patients who have severely limited treatment options. The positive trial results could lead to regulatory approval, broadening access to this innovative therapy and potentially improving patient outcomes significantly. Regulatory stability is on the horizon with the FDA appointing permanent heads for its Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER). This leadership continuity is crucial as it supports the agency's ongoing restructuring efforts aimed at enhancing efficiency and oversight. Stable leadership within these centers ensures rigorous drug evaluation processes continue, which is critical for timely approvals and has a direct impact on drug developers' strategic planning and market entry timelines. Clinical trials continue to yield varied results, showcasing the inherent uncertainties in drug development. AstraZeneca's Tozorakimab showed promise with approximately a 30% reduction in exacerbations in Phase 3 trials for chronic obstructive pulmonary disease (COPD), hinting at improved management of respiratory diseases through targeted monoclonal antibody therapies. Conversely, challenges persist as Evommune's Evo756 did not meet its Phase 2b trial expectations for atopic dermatitis, and Tyra Biosciences' Dabogratinib fell short in non-muscle invasive bladder cancer trials—highlighting the unpredictable nature of clinical research. Investment flows into biopharmaceuticals remain robust, with Encoded Therapeutics raising $275 million to advance its gene therapy program for Dravet syndrome. Similarly, Luma Group has secured $410 million for ventures focusing on ophthalmology and cellular rejuvenation technologies. Such investments reflect strong confidence in gene and cell therapies' transformative potential on patient care. On the mergers and acquisitions front, Sernova Biotherapeutics' merger with Seraxis to form Betanova Biotherapeutics exemplifies how companies are consolidating expertise to enhance R&D capabilities and expand their market reach, particularly in cell therapy solutions for diabetes management. These strategic consolidations indicate ongoing efforts to leverage synergies that could redefine therapeutic landscapes. The biopharmaceutical sector is also seeing shifts due to ongoing geopolitical tensions between the U.S. and China, pushing companies to seek investment opportunities outside China. This diversification strategy aims to mitigate geopolitical risks while continuing global innovation efforts. In obesity treatment research, partnerships like those between GemPharmaTech signal new frontiers beyond GLP-1 receptor agonists. These collaborations highlight an industry commitment to tackling global health challenges with innovative therapies that prioritize efficacy and safety. These developments collectively paint a picture of a dynamic industry marked by scientific breakthroughs, strategic investments, regulatory evolution, and significant challenges in clinical trials. As these sectors evolve, they promise exciting advancements that could profoundly redefine global healthcare paradigms. The focus remains on overcoming therapeutic barriers through sustained research efforts and innovative approaches—a testament to the industry's relentless pursuit of improving patient care outcomes worldwide.Support the show

Social media is full of people promising fast money, six-figure months and millionaire lifestyles. Anthony O'Neal says the numbers tell a very different story: Americans can earn well and still have little margin, heavy debt and no real financial security.In this episode, Anthony steps into professor mode to break down his five-phase Escape Plan for building financial freedom in the right order. Using the real-life example of a 34-year-old earning $6,000 a month but spending $6,400, Anthony walks through how to create margin, eliminate consumer debt, build an emergency fund, invest consistently and prepare a legacy that protects the people you love. The goal isn't to look rich. It's to build a financial life strong enough to give you freedom, security and options.Mentioned Here:

Stop resetting your Meta ads learning phase. Most sellers waste budget by tinkering with campaigns that need time to optimize. of The High Voltage Business Builders Podcast, Krista Karpan explains why broad targeting and creative diversity matter more than hyper-specific interest lists in 2026. You will learn how to structure CBO campaigns for better efficiency and avoid the common mistake of killing ads too early. If you spend the next 30 minutes listening, your ad account will stop bleeding money on unnecessary adjustments. You will understand why the Andromeda update requires true creative variety, not just minor tweaks to existing winners. This is critical for any brand spending between $5,000 and $100,000 a month on paid social. We break down the exact budget minimums and ad set structures that prevent wasted spend. You will see how one perfume brand scaled their return on ad spend from 3.46 to 4.82 by letting the algorithm do its job. The key is stopping the constant fiddling that resets performance data. Your operation improves when you trust the system and focus on creative strategy instead of backend management. You will get a clear framework for launching new campaigns without drowning in data. Listen now to fix your Meta ads strategy and protect your margins. Apply these three moves to your account today. Stop guessing and start scaling with confidence. Get the five ecommerce updates that matter every Tuesday and Friday at voltagedm.com/newsletter: https://voltagedm.com/newsletter?utm_source=rss&utm_medium=show_notes&utm_campaign=ep381

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we unveil a series of transformative strides in drug approvals, clinical trials, and regulatory landscapes that are reshaping the future of patient care. AstraZeneca's camizestrant, now branded as Etcamah, has received FDA approval for treating ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer. This approval is a testament to the potential of selective estrogen receptor degraders (SERDs) in oncology. The Phase 3 trial results highlight camizestrant's efficacy when combined with CDK4/6 inhibitors, offering a tailored therapeutic strategy for patients with ESR1 mutations. Such advancements in personalized oncology are steering the industry toward more precise treatment paradigms. Complementing this approval, Guardant Health's Guardant360 CDx has been sanctioned as a companion diagnostic tool for camizestrant. The liquid biopsy-based method precisely identifies ESR1 mutations, underscoring the growing reliance on precision diagnostics in cancer management. As precision medicine continues to evolve, integrating diagnostics with therapeutics becomes crucial in achieving optimal patient outcomes. Bristol Myers Squibb has made headlines with its CAR-T cell therapy, arlocabtagene autoleucel, showing efficacy in its Phase 3 trial for GPRC5D-targeted relapsed or refractory multiple myeloma. This advancement reflects the burgeoning application of cell-based treatments in hematological malignancies and signals a shift towards personalized immunotherapy strategies promising improved patient outcomes. On a related note, Brainchild Bio's significant $116 million fundraising initiative aims to advance CAR-T therapies tailored for childhood brain cancers. This development highlights the potential of CAR-T technology beyond hematologic cancers and indicates an intensified focus on pediatric oncology therapeutics. In regulatory news, Shionogi's cefiderocol has gained approval from Australia's Therapeutic Goods Administration (TGA) for combating carbapenem-resistant gram-negative bacterial infections. Cefiderocol addresses critical needs in combating multidrug-resistant pathogens, particularly in urinary tract infections, and highlights ongoing global efforts to tackle antimicrobial resistance. Clinical trials continue to yield promising outcomes. Pharvaris' deucrictibant showcased positive results in its Phase 3 trial for hereditary angioedema by effectively targeting the bradykinin B2 receptor. Novo Nordisk's semaglutide (Wegovy) demonstrated remarkable efficacy in reducing obesity among children during its Phase 3 trials. These results emphasize continued innovation in treating metabolic disorders and rare diseases by leveraging small molecule therapeutics and receptor modulators. Not all developments have been positive. Novartis and Ionis Pharmaceuticals faced setbacks with pelacarsen failing to meet endpoints in a Phase 3 trial aimed at reducing major cardiovascular events despite lowering lipoprotein(a). This underscores the challenges of translating promising biomarkers into effective therapeutic interventions. Regulatory challenges were also observed as American Regent recalled batches of epinephrine due to contamination issues, and Boston Scientific recalled spinal cord implants linked to serious injuries. These instances underscore the importance of stringent quality control and regulatory compliance to ensure patient safety. Meanwhile, Amgen's DLL3-targeted therapy, Imdelltra, achieved an overall survival win in a first-line setting for small cell lung cancer (SCLC), although specific numerical results were not disclosed. This bispecific antibody could set a new standard for early intervention in SCLC, emphasizing the potential of targeted therapies in improving survival rates for aggressive cancers. In other advancements, Roche continues to dominate neurology with top positions in corporate reputation rankings within this therapeutic area. This accolade reflects Roche's commitment to innovation and patient-centric approaches to managing neurological disorders. As these developments unfold across various domains of pharmaceutical innovation and regulation, they collectively signal a dynamic era for the industry marked by rapid scientific progress and evolving treatment strategies. The implications are profound, offering potential improvements in patient outcomes through more targeted therapies while highlighting challenges such as clinical trial failures that necessitate continued diligence in drug development strategies. As these trends unfold, they hold promise for significant advancements in treatment efficacy and safety across various therapeutic areas. Thank you for tuning into Pharma Daily. Stay informed about the latest industry developments as we continue to explore the dynamic landscape of pharmaceutical innovations together.Support the show

Mark Allen of Colliers- Dallas joins the Old Capital Real Estate Investing Podcast to explain how distressed properties, forced sales, and lender-owned assets are reshaping the multifamily market. According to Mark, nearly 60% of apartment sales during the first half of 2026 involved properties built before 1990—evidence that workforce housing has moved to the center of the market.   "I look at this as really the resolution phase of the market, so we're starting to resolve a lot of this distress," Mark explains. High-net-worth investors now represent many of the buyers pursuing these opportunistic acquisitions, replacing some of the traditional syndication groups that previously dominated bid sheets. For sellers, Mark says the most important consideration is no longer necessarily the highest offer: "Surety of close is key in today's market. Not price—surety of close."   Mark also describes two extraordinary transactions in which sellers are willing to pay buyers to assume loans and avoid agency foreclosures—something he has never witnessed during his career. Although today's market remains challenging, he believes some properties are trading at values that could eventually produce exceptional returns as demand and rent growth recover. "At some point, they're going to look great," Mark says, predicting that certain properties could eventually trade for twice their current purchase prices.  "If you felt like you missed the opportunity 10 years ago, we're back—same pricing, same opportunity."   His advice to sellers is to carefully investigate each buyer's transaction history and personally contact their references. His advice to buyers is equally direct: "Location is key," and investors entering difficult submarkets should have sufficient capital to withstand a potentially extended recovery. In today's market, Mark believes being overcapitalized is far wiser than being undercapitalized.   Paul also shares how the Old Capital Accelerator provides hands-on education, property tours, and practical experience for investors who want to grow into multifamily ownership.   Learn alongside experienced apartment owners, brokers, property managers, attorneys, and other industry professionals as we walk through the entire acquisition process—from finding and underwriting deals to financing, due diligence, raising equity, and submitting an offer. This isn't about theory. It's about learning how apartment deals actually get done in today's market. Real Deals. Real Experts. Real-World Experience.   Learn more and apply to the Old Capital Multifamily Accelerator: OldCapitalAccelerator.com

This episode is sponsored by Masterclass. MasterClass - MasterClass keeps adding new classes, so there's never been a better time to get in. Head to https://masterclass.com/flipping50 to get at least 15% off any annual membership. PMOS hormones and metabolism are connected in ways that can change how you understand your body in midlife. PCOS has a new name—and it changes the conversation In this episode, learn what to watch for and what changes during perimenopause. Some symptoms, metabolic changes, or health risks showing up in midlife have roots that go much further back than menopause. If you've ever wondered how your past could still influence your health today, this conversation will change how you think about PMOS hormones and metabolism. My Guest: Dr. Anne Hussain is a Naturopathic Doctor, Menopause Society Certified Practitioner, TEDx speaker, author of The Period Literacy Handbook, and co-creator of The Perimenopause Summit. Her passion to empower and support women with evidence-based care through every stage of their hormonal lives stems from her own PMOS and lack of reproductive health education growing up in Pakistan.  Anne runs a hybrid clinical practice in Ontario, Canada. She hosts Phase to Phase: The Hormone Health Show, trains clinicians, and collaborates with menstrual equity organizations. She believes that developing agency over your health is not only a personal act but also a powerful, political tool for shaping a healthier world. Questions We Answer in This Episode: [00:05:50] PCOS to PMOS name change: Why and what does it mean? [00:12:56] Why has PMOS often gone undiagnosed in the past, especially in women now in midlife? [00:22:58] What is the specific diagnostic criteria for PMOS? [00:26:00] How do doctors approach treatment for PMOS without just "playing whack-a-mole" with symptoms? Connect with Dr. Anne: Join Dr. Anne's The Perimenopause Summit on Sept 21 to 24, 2026 FREE through this link: https://www.flippingfifty.com/theperimenopause  Facebook - Dr. Anne Hussain Instagram - @dr.annehussain LinkedIn - Dr. Anne Hussain Connect with Flipping 50: Facebook Group - Flipping50 Insiders Instagram - @Flipping50TV YouTube - @Flipping50TV More Episodes - Flipping 50 The Stronger Way

Is obesity still a disease worthy of treatment when the patient is six years old?This week, Novo Nordisk released Phase 3 STEP Young data in children ages 6 to 11 with obesity. After 68 weeks, 40.4% of children treated with semaglutide moved below the obesity threshold, compared with 0% on placebo. More than 85% of the children entered the trial with class II or class III severe obesity, and both groups received lifestyle intervention.That raises a harder question than whether people are comfortable with kids taking GLP-1s: compared with what? A nearly 90% chance that obesity present at age 3 persists into the teen years? An approximately 80% chance that a teen with obesity carries it into adulthood? Another decade of stigma, bullying, and metabolic disease while we keep telling families to try harder?I'm unapologetically supportive of studying and treating severe childhood obesity. That does not mean ignoring long-term questions around growth, puberty, nutrition, lean mass, or what happens when treatment stops. It means recognizing that withholding treatment is also a decision with consequences.We also break down the new Structure Therapeutics data, including aleniglipron, an oral small-molecule GLP-1 that produced up to 16.2% mean weight loss at 72 weeks, and ACCG-2671, an experimental oral amylin/calcitonin agonist that produced 3.3% mean weight loss after a single dose, with some important tolerability caveats.Plus, we look at a preliminary semaglutide signal involving asthma and COPD, and one of the strangest Ozempic access stories of the week.Recorded from the Bask Health Studios.This episode is sponsored by VoaFit. Learn more about VoaFit here:https://voafit.com/otpThis episode was filmed in the Bask Health Studios, visit:https://bask.healthFollow On The Pen everywhere plus get special discounts:https://otplinks.comRead more at:https://obesity.news

Follow the Mister Benfica Podcast Channel on https://episodes.fm/1463340370Then select your favor podcasting platform!The Mister Benfica Podcast Channel presents this fifth season of a spin-off Podcast taking you to small and medium sized towns and cities of Portugal each week with a rapid paced recap of the action in Portugal's third division. Liga3 em Inglês will keep Benfica Nation up to date with clubs big or small from our different hometowns and regions as they fight for the dream of promotion and against the nightmare of relegation. Jump in and come for a ride around the Liga 3 with the Mister @MikeAgostinho#Liga3 #PuroFutebolFollow the show on the platforms below:Twitter   Instagram  Facebook Apple Podcasts  Spotify  PodbeaniHeartRadio  Amazon Music/AudibleFor more content check out  www.parkingthebusmedia.comwww.misterbenfica.com

For the first time in history, a personalized mRNA cancer vaccine has passed a Phase 3 clinical trial. Robert Lufkin MD breaks down the Moderna/Merck melanoma result, how a vaccine custom-built from your own tumor actually works, the 49% drop in recurrence risk behind the headlines — and the honest answer to whether mRNA vaccines will cure cancer. In this episode of Health Longevity Secrets, Robert Lufkin MD explains the science of personalized mRNA cancer vaccines: neoantigens, the AI-designed "most wanted poster" for your immune system, the five-year KEYNOTE-942 data, the stunning pancreatic cancer signal from Memorial Sloan Kettering, the BioNTech colorectal trial shutdown that reminds us why we run trials — and what still sits upstream of it all: your metabolic health. Chapters: 00:00 — Introduction: A Cancer Vaccine Makes History 00:43 — What Just Happened: Moderna/Merck Phase 3 Melanoma Trial 01:44 — A Vaccine Made From Your Own Tumor: How It Works 02:31 — Neoantigens: A "Most Wanted Poster" for Your T-Cells 03:17 — The Numbers Behind the Hype: 49% Lower Recurrence at 5 Years 03:53 — Pancreatic Cancer Vaccine: The Sloan Kettering Survival Signal 04:44 — So Will mRNA Vaccines Cure Cancer? The Honest Answer 05:40 — The Platform Play: Lung, Kidney & Prostate Cancer Trials 06:09 — The Honest Caveats: Press Releases vs Peer Review 06:45 — The Colorectal Trial Shutdown: A Reality Check 07:57 — The Takeaway: Metabolic Health Still Sits Upstream Key takeaways: Intismeran autogene + Keytruda is the first mRNA cancer vaccine to succeed in a Phase 3 trial — FDA approval possibly by early 2027. These are NOT prevention shots — each dose is custom-built from one patient's tumor mutations to hunt residual cancer cells after surgery. Five-year Phase 2b data (KEYNOTE-942): 49% lower risk of recurrence or death, and 62% lower risk of distant metastasis or death at three years. Pancreatic trial (n=16): ~90% of immune responders alive 4–6 years after surgery vs ~25% of non-responders — hypothesis-generating, not proof. The reality check: BioNTech/Genentech halted a colorectal Phase 2 after MORE deaths in the vaccine-alone arm — same technology, different cancer, opposite result. The Phase 3 result is a top-line press release, not yet peer-reviewed; the vaccine is not FDA-approved and is only available in clinical trials today. Muscle, blood sugar control, sleep, not smoking, and sun protection remain the most proven cancer-risk tools you own right now. Studies & sources: Merck/Moderna press release (Aug 19, 2026) — Phase 3 INTerpath-001: intismeran autogene + Keytruda met RFS & DMFS endpoints Nature news — Personalized Moderna/Merck mRNA vaccine reduces melanoma recurrence in Phase 3 Weber et al., J Clin Oncol 2026 — 5-Year Update of KEYNOTE-942 (49% recurrence/death reduction) Rojas et al., Nature 2023 — Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer (MSK) BioNTech statement (Aug 28, 2026) — Phase 2 colorectal trial of autogene cevumeran terminated ABC News — Personalized mRNA cancer vaccine shows promise Dr. Lufkin's book Lies I Taught in Medical School — more at robertlufkinmd.com and the Health Longevity Brief on Substack. ⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!New episodes every other Tuesday. Subscribe so you don't miss one.Continue this conversation on Substack: https://robertlufkinmd.substack.comLies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/Web: https://www.robertlufkinmd.comYouTube: https://www.youtube.com/robertlufkinmdX: https://x.com/robertlufkinmdInstagram: https://www.instagram.com/robertlufkinmd/TikTok: https://www.tiktok.com/@robertlufkinLinkedIn: https://www.linkedin.com/in/robertlufkinmd/

I've taken two maternity leaves, recovered from shingles, herniated two discs in my neck, and navigated extended time away for grief. None of those were things I saw coming except for one, and the difference between the leaves I was prepared for and the ones I wasn't was everything. This is one of the most requested topics I get from stylists and salon owners, and today I'm finally bringing it to the podcast. Whether you're planning a maternity leave, staring down a medical situation, or just a human being who could face an unexpected leave at any point, the systems and strategies I'm sharing in this episode are what's going to protect your clientele and your income when life happens. A 15% client loss during a leave is normal. Anything more than that is a systems problem, and that's exactly what we're solving today!  Get up to $200 off Square hardware when you sign up at square.com/go/thriver! #squarepod #sponsored All the episodes of After The Last Client are now available! Head over to www.afterthelastclient.com/ to watch the episodes, binge the series, and nominate the guests you want to see featured next season. Do you have a question for me that you'd like answered in a future episode like this one? A great way to do that is to head over to Apple Podcasts and leave a rating and review with your question. I'm looking forward to answering your question on a future episode on the podcast!  If you're not already following us, @thethrivingstylist, what are you waiting for? This is where I share pro tips every single week, along with winning strategies, testimonials, and amazing breakthroughs from my audience. You're not going to want to miss out on this. Learn more at: https://thrivingstylist.com/podcast/ 

Most clinicians wait too long to introduce sprinting mechanics in rehab, then wonder why the jump to full speed feels like zero to a hundred.John Allan Furgeson, DPT, sits down with Dr. Azita Nejaddehghan to break down how to scale acceleration and deceleration work down to technical, low-load pieces early in the rehab process instead of saving them for the final phase. Sprinting phases can be trained at submax-effort while isolating movement patterns and muscles before getting back to max-effort sprints. What they cover:Why deceleration training and eccentric strength work are not the same thing, and how to train deceleration early using yielding and overcoming isometricsHow to isolate sprint phases like late swing to prove to an athlete their body can tolerate the pattern before testing max effortMatching objective testing with visual observation to find the real rate-limiting deficit, strength, confidence, or something else entirelyWhy an experienced athlete's subjective feedback on compensation is an underused diagnostic toolThe control-to-chaos continuum: moving return-to-sport from anticipatory to reactive, individual to team, closed to openWhy every clinician should get on the field and sprint and cut themselves before programming it for someone elseRehab doesn't fail at max effort. It fails months earlier, when nobody trained the pattern at all.Social Media:Rehab2PerformR2P AcademyDr. Azita Nejaddehghan

Sunday, September 6, 2026 — Week 36

Episode 406 explains how movement prepares the brain but does not guarantee learning. It traces the full sequence—movement, RAS-driven readiness, salience and relevance, focused attention, encoding, retrieval and repetition, and recovery and sleep—that turns activation into lasting memory and performance. The episode offers practical steps in a Move–Focus–Learn protocol: use brief movement to create readiness, clearly identify and remove distractions for one learning target, interact with material in meaningful ways, practice retrieval and spaced repetition, and protect recovery to support consolidation. Listeners are encouraged to test these simple experiments for school, work, or personal learning to make experience more usable and improve attention, memory, and performance. ON THIS EPISODE, YOU'LL LEARN: ✔ Why movement prepares the brain but does not guarantee learning ✔ How attention directs the capacity movement creates ✔ Why meaning and emotional relevance capture attention ✔ The difference between paying attention and actually learning ✔ How retrieval and repetition help new information stick ✔ How seeing, hearing, explaining, and applying an idea can help us remember it ✔ How restorative sleep supports memory and learning ✔ A practical Move–Focus–Learn Protocol for school, work, or your own personal learning The central idea is simple: Movement opens the window. Attention determines what enters. Repetition strengthens what remains. And recovery helps the brain integrate what it has experienced. Welcome back to the Neuroscience Meets Social and Emotional Learning Podcast, where we bridge neuroscience, social and emotional learning, and human performance so we can create measurable improvements in our well-being, achievement, leadership, productivity, and results. I'm Andrea Samadi, and if you've been following along through Season 16, you'll know that we have been building what I call The Brain's Operating System for Human Performance—a neuroscience-based framework designed to help us understand how the different systems of the brain and body work together to influence how we learn, adapt, connect, lead, and ultimately, how we perform. We are currently in Phase 3, focused on Movement, Learning, and Cognition. As I prepared for this phase, I went back through more than 400 episodes of the podcast and organized them according to the five phases of this framework. I wanted to see whether any patterns would emerge. And some did. Phase 1, Regulation and Safety, includes 57 episodes. Phase 2, Neurochemistry and Motivation, includes 41 episodes—the smallest category, possibly because this is the area I have explored the least with my learning. Phase 3, Movement, Learning, and Cognition, includes 174 episodes—the largest category by far. Phase 4, Perception and Social Intelligence, includes 68 episodes. And Phase 5, Integration and Meaning, includes 71 episodes. When I saw that 174 episodes—more than 40 percent of the entire podcast—fit into Movement, Learning, and Cognition, it immediately showed me where much of my curiosity has been directed over the years. I have always been fascinated by learning: How do we prepare the brain to learn? What captures our attention? Why do some ideas (or people) remain with us while others disappear? How does knowledge become something we can retrieve, apply, and actually use to improve our lives? And while I am spending most of my spare time hiking, or at the gym over the years, I wonder, how does this movement that I'm doing help to improve my attention, or memory, and finally, where does recovery fit into this process? The past few weeks, I'm finally connecting the dots with how important recovery is with this equation. I'm also learning how to determine what's important to me. John Medina's Brain Rules book explains what holds our attention. He reminds us that “we don't pay attention to boring things (or people).[i] As we continue through these five phases of The Brain's Operating System for Human Performance, I'm especially curious about how we will move beyond understanding these lessons, to begin implementing what we are learning, and connecting more ways to improve how we learn, adapt, connect, lead, and ultimately perform in our day to day lives. That will become an important part of the upcoming workbook—which is a practical way for each of us to identify what we have already strengthened, where gaps may remain, and which specific actions can help us to improve our own learning, well-being, and performance. Because the purpose of this 5 Phase Framework is not simply to collect more information about the brain. It is to understand how the systems connect—and then use that understanding to create meaningful change.  “Attention Is the Gate—How Movement Becomes Learning.” For today's Episode 406, we'll connect Dr. John Medina's Brain Rules to the Movement Loop we have been building throughout Phase 3—and answer the next important question: Once movement activates and prepares the brain, what determines whether that readiness becomes lasting learning? You can review our full interview with John Medina from EP 42[ii] from February 2020. (find the link in the reference section of the show notes). INTRODUCTION: THE MISSING STEP We have spent this phase so far, examining how movement changes the brain. Dr. Chuck Hillman and Paul Zientarski[iii] showed us that movement prepares the brain for learning. Dr. John Ratey[iv] helped us understand how exercise influences neurochemistry, BDNF, and neuroplasticity. Dr. Kristen Holmes[v] showed us that recovery helps determine whether strain becomes adaptation. And our restorative-sleep episode explored where some of that recovery, adaptation, and integration may occur. But one important question remains: A brain can be activated, chemically prepared, and physiologically ready—but what determines what it actually learns? The answer begins with attention. Movement may create the readiness to learn, but readiness alone is not learning. The brain must still select what matters, focus on it, interact with it, encode it, revisit it, and eventually integrate it. That gives us the pathway we will explore today: Movement creates readiness. But what is the filter in our brain that helps us to focus on the things that are most important to us. What gives us the ability to pay attention to something? The RAS- or The Reticular Activating System. Before we continue, let's remind ourselves what the RAS is. The RAS—or reticular activating system—is a network of neurons extending through the brainstem that helps regulate wakefulness, alertness, and our readiness to respond to incoming information. We explored this system previously in Episode 272, “Priming the Reticular Activating System to Achieve Our Goals.” In that episode, we described the RAS as a type of filter that helps us notice information connected to what we have identified as important. For example, once you decide that you are interested in a particular type of car, you may suddenly begin seeing that car everywhere. That's the RAS filtering system in our brain. The cars were already there, but your attention now has a reason to prioritize them. In Episode 272[vi], we applied this idea to goal-setting. When we clearly identify an intention, we may become more likely to notice relevant information, opportunities, and connections that were previously present but did not receive our attention. That explanation gave us a useful starting point. But here in Episode 406, we can add more precision. The RAS is not a tiny gatekeeper sitting in the brain and personally deciding what we will learn. It is part of a broader network that helps maintain the level of arousal and alertness required for our attention. It helps the brain become available to notice whatever it is that is important to us. Then salience, relevance, emotion, intention, and our current goals help determine what receives priority. Focused attention directs our limited cognitive resources toward the selected information. Next, encoding and repetition help strengthen what we want to focus on. And recovery and sleep help to further support its consolidation and integration. So our expanded Movement Loop now looks like this: you can see an image in the show notes to expand this understanding. Movement supports brain activation.   RAS helps the brain become awake, alert, and ready to pay attention. Salience and relevance (or what matters the most to us) helps to determine what receives priority. Our focused attention selects what gets our priority. Encoding and repetition further strengthens this pathway. Recovery and sleep (that we've dove deep into) support consolidation and integration. And together, these processes increase the likelihood that experience becomes learning—and that learning becomes available for future performance. Whatever it is that we have put our attention on, is now made usable.  This shows us how our understanding has evolved since Episode 272, three years ago. Then, we were asking: How can our intention help us notice what matters with the attainment of our goals? Now, years later, with more understanding, we are asking: Once the brain is alert and something important has captured our attention, what sequence of events must occur for that information to become lasting learning? We are no longer asking only what must remain top of mind so we can notice opportunities connected to our goals. We are asking what happens next: How does something we notice become something we understand? How does something we understand become something we remember? And how does something we remember become knowledge or a skill we can retrieve, apply, and use to improve our performance? This is where Dr. John Medina's Brain Rules help us to connect the pieces. Let's begin with Lesson One: Lesson 1: Movement Creates Readiness—Not Guaranteed Learning Movement can increase alertness, circulation, and readiness for cognitive work. But why might movement have such a powerful relationship with the brain? Dr. John Medina explains this through an evolutionary lens. His point is that the human brain did not develop while we were sitting motionless at desks or staring at screens. It developed while human beings were moving through changing outdoor environments, solving immediate problems, and continually responding to the world around them. Let's listen to how he explains it. CLIP 1 John Medina “The human brain was designed to solve problems related to surviving in an outdoor setting, in unstable meteorological conditions—and to do so in constant motion. The constant motion is where the exercise comes in. But the rest of that—the more a school, or any of us, can recreate the world of the Serengeti, the place where this brain actually grew up, the better things are. And exercise, particularly outdoor exercise, is a terrific example of this idea.” When Medina refers to the Serengeti, I don't think he is suggesting that schools should literally recreate the dangers or conditions of an ancient environment. He is giving us an evolutionary picture of the conditions under which the human brain developed: We moved. We navigated changing environments. We encountered new sensory information. We solved problems. We adapted to uncertainty. And we did these things together rather than remaining physically still for most of the day. Outdoor movement may bring several of these conditions together. We are moving our bodies while also responding to changes in light, temperature, terrain, sound, distance, and direction. This helps explain why movement belongs at the beginning of our Movement Loop. But it also brings us to an important distinction: Movement creates readiness. It does not guarantee learning. A student can move before class and still become distracted. A leader can exercise before work and still spend the morning reacting to notifications. An athlete can warm up physically without becoming mentally focused on the strategy or skill required next. Movement can help activate the system. The RAS in the brain helps us become awake and alert. But the brain must still determine what stands out, what is relevant, and what deserves focused attention. Movement opens the window. Attention determines what enters through it. Our Key lesson: Movement prepares the brain. Attention directs the preparation. PUT THIS INTO ACTION Before your next period of demanding cognitive work, use movement to create a window of readiness. Take a five-to-ten-minute walk, complete a brief movement break, stretch, or choose another form of movement appropriate for your ability and environment. But do not move without deciding what comes next. Before you begin, identify the specific task you will return to: “When this movement break ends, what will receive my attention?” For a student, it might be the first problem on a math assignment. For a leader, it might be the one decision that requires uninterrupted thinking. For an athlete, it might be the cue, strategy, or skill that needs to remain at the center of practice. Movement creates the opportunity. A clear intention helps direct what happens next. Your experiment is: Move briefly, choose one target that you want to complete with this intention, and begin that task immediately after the movement ends. Lesson 2: Attention Is the Gate In EP 395[vii], we examined what captures attention: Meaning Emotion Relevance Intention Reward Human connection Now today's episode shows how we move beyond why the brain notices something and explains what attention does after movement has prepared the system to learn. Attention acts as a filter. The brain encounters more information than it can consciously process, so it must select what receives priority. This creates the bridge: Brain activation creates capacity. Attention distributes that capacity. Our Key lesson: What the brain does not attend to has little opportunity to become lasting learning. Andrea's Application This distinction between brain capacity and cognitive efficiency became personal for me when I reviewed the results of my 2020 brain scan. We covered this topic on EP 84[viii] and we will do a thorough review of what was learned with our brain scans at Dr. Daniel Amen's CA Clinic. The evaluation that I received after my scan was completed with Dr. Shane Creado, suggested that I had areas of strong capacity, but that my brain appeared to be working harder than necessary to complete certain tasks in the cognitive testing. A possible contributor we discussed was sleep deprivation. I want to be careful here: a SPECT scan is not a direct measurement of attention or learning, and my results cannot tell us that insufficient sleep caused a specific attention pattern. But the experience gave me a useful way to think about what we are learning today. Having cognitive capacity does not necessarily mean that we are using that capacity efficiently. I may be motivated, active, and ready to work—but if I am under-recovered, under-slept, distracted, or trying to process too many competing inputs, my brain may have to expend more energy to sustain focus. This helped me understand the Movement Loop at a more personal level: Movement can help activate my brain. Attention gives that activation a target. But recovery may influence how efficiently I can sustain that attention and use it for learning. My scan did not define what my brain could do. It gave me another reason to examine the conditions under which my brain performs at its best. PUT THIS INTO ACTION Before asking yourself—or someone else—to focus, make the target of attention clear. Start by completing this sentence: “The most important thing to notice right now is…” Then reduce the competition around it. We all know to do this. Silence unnecessary notifications. Close unrelated tabs. Remove extra materials from view. Avoid asking the brain to switch repeatedly between tasks. If you are teaching, make the relevance visible: “Why does this matter?” “What should students be listening or looking for?” “How does this connect to something they already know?” If you are working independently, write your one priority clearly where you can see it. Remember, the goal is not to force the brain to attend to everything. The goal is to help it identify (with your RAS-that filter in your brain) what deserves your priority. Your experiment is: Choose one target, (something you want to accomplish) remove as many unnecessary sources of interference as possible, and create one meaningful reason to pay attention. This also helps explain why keeping your desk clear, your closet organized, or your car tidy may make you feel calmer and more focused. How we do anything is how we do everything. Every object, notification, unfinished task, or piece of visual clutter can become another potential signal competing for your attention. That does not mean everything must be perfectly organized before you can begin (while some of us would prefer to work this way), perfection can become its own form of interference. Just get started. It simply means that when you reduce unnecessary visual and mental competition, you make it easier for the brain to recognize the priority in front of you. Clear the space. Name the target. Create the relevance. Then give the task your full attention. Lesson 3: Attention Is Necessary—but It Is Not Enough Paying attention to information once does not guarantee that it will be remembered. This is where Dr. Medina's memory rules enter: Repeat to remember. Remember to repeat. The first refers to giving new information more than one opportunity to be encoded. The second points toward revisiting information over time. This allows you to extend the Movement Loop: Movement prepares the brain and body. Attention selects what to focus on. Retrieval and Repetition strengthens our focus. Recovery helps us to integrate what we are learning. PUT THIS INTO ACTION After learning something new, do not immediately reread it. First, look away from the material and try to retrieve it. Ask yourself: “What were the three most important ideas?” “How would I explain this without looking at my notes?” “What can I remember on my own?” Retrieval reveals the difference between recognizing information and actually being able to access it. Then return to the material, check what you missed, and retrieve it again later—after an hour, the next day, or several days afterward. For students, this could mean closing the textbook and explaining the lesson to a partner. For professionals, it could mean summarizing a meeting before reviewing the notes. For personal learning, it could mean recording a short voice memo explaining the idea from memory. Your experiment is: Learn it once, retrieve it without looking, and schedule a brief return to it later. See if you can remember it. Attention begins the pathway. Retrieval and repetition help strengthen it. Andrea's Application This lesson reminded me of one part of the cognitive testing that accompanied my brain scan at Amen Clinics: a Continuous Performance Test, or CPT. In the version I completed, letters appeared on a computer screen. The instruction was to press a button whenever a letter appeared—except when the letter was X. This type of task may sound simple, but it requires you to remain attentive over time, respond consistently, and inhibit your automatic response when the target letter appears. My results indicated that this was an area in which I did not perform as strongly. Looking back, I remember hearing the basic instruction: press the button for every letter except X. But I do not remember fully appreciating that the speed and consistency of my responses also mattered. This gave me an important real-life lesson: Hearing an instruction is not the same as accurately encoding everything the task requires. Before beginning something important, pause and ask: “What exactly am I being asked to do?” “What details determine successful performance?” “Can I explain the instructions back in my own words?” And, when appropriate, write down the key steps before beginning. This applies in a classroom, during a meeting, while completing an assessment, or whenever accuracy matters. First, attend to the full instruction. Then restate or retrieve it. Clarify anything that is missing. And only then begin the task. My experience showed me that attention is not just about working harder or concentrating more intensely. It is also about identifying the correct target—and making sure we understand the complete task before directing our effort toward it. Lesson 4: Learning Becomes Stronger When It Has More Than One Path Dr. Medina's Brain Rule #9 about sensory integration and vision(meaning our brains learn and remember best when multiple senses—like sight, sound, and touch—are engaged at the same time) give you the practical learning background to involve ALL of your senses. While teaching and learning you can ask: Can I see it? Can I hear it? Can I explain it? Can I demonstrate it? Can I connect it to something I already know? Can I apply it physically or practically? The goal is not sensory stimulation for its own sake. It is to provide clear, relevant pathways through which the learner can interact with the information. Our Key lesson: The more meaningfully we interact with information that we are learning, the more opportunities the brain has to encode and retrieve it. PUT THIS INTO ACTION Choose one idea you want to remember and interact with it in at least two meaningful ways. You might: See it in a diagram. Hear it explained. Say it in your own words. Write or draw it. Teach it to someone else. Demonstrate it physically. Connect it to a previous experience. Or apply it to a real problem. The goal is not to add noise or stimulation. More input is not automatically better. Each interaction should make the idea clearer, more relevant, or easier to retrieve. For example, instead of only reading about the Movement Loop, you could draw the sequence, explain it aloud, and identify where it appears in your own daily routine. Your experiment is: Take one important idea and represent it in two different, meaningful ways. The more deeply we work with information, the more opportunities the brain has to encode and retrieve it. Andrea's Application If you have been listening to this podcast for a while, I'm sure you have noticed that when I organize an idea into a framework—or represent it in a visual graphic—it begins to come to life. I can see how the pieces from past episodes connect, can explain the concept more clearly, and retrieve and apply it to my life more easily. It's also difficult to forget something when there's a visual image connected to it if you are the type of learner who needs to see something to make it stick in your memory. LESSON 5: RECOVERY HELPS LEARNING CONTINUE AFTER ATTENTION ENDS So far, we have followed learning through four important steps: Movement prepares the brain and body. RAS helps “turn on the lights,” allowing us to become awake, alert, and ready to respond. Next, the brain begins identifying what might be important to us. Salience refers to something that stands out—perhaps because it is new, unexpected, emotional, or connected to a possible reward or threat. Relevance refers to how closely that information connects to our goals, needs, experiences, or interests. In simple terms: Salience asks, “What stands out?” Relevance asks, “What matters to me?” Attention through the RAS next directs the brain's spotlight toward the information selected for deeper processing. Imagine a flashlight shining on whatever it is that you have picked to be important to learn. Encoding creates the initial memory. Retrieval and repetition strengthen it. But learning does not necessarily end when we close the book, leave the classroom, finish the meeting, or stop practicing. The brain still needs time to stabilize, organize, and connect what we learned. This is where recovery and sleep enter the Movement Loop. SLEEP IS AN IMPORTANT PART OF LEARNING Sleep is not a period when the brain simply switches off. While we sleep, the brain continues processing information from the day. Newly encoded memories may be reactivated, strengthened, reorganized, and connected with knowledge we already have. This is called memory consolidation. In simple terms, consolidation helps make a new memory more stable and easier to access later. Deep non-REM sleep and REM sleep may support different but overlapping parts of this process. Deep sleep is associated with physical restoration and the consolidation of certain facts and experiences. REM sleep has been associated with emotional learning, procedural skills, creative connections, and integrating new experiences with older memories. But we should not think of these as completely separate jobs. Deep sleep and REM are parts of a repeating sleep cycle, and both may contribute to learning. This is why I use the phrases: Deep sleep helps me recover from the hard work I did that day. REM may help me integrate what I experienced and what it meant to me. The word “may” matters because sleep is more complex than saying that deep sleep only restores the body and REM alone integrates learning. The most important lesson is this: What we focus on while we are awake gives the brain something to work with while we sleep. Retrieval and repetition strengthen the information before sleep. Then sleep provides conditions that can help stabilize, organize, and connect what we learned. THE MOVEMENT LOOP IN SIMPLE TERMS Let's put the complete cognitive side of the Movement Loop into simple language. MOVE—to prepare the brain and body. BECOME READY—RAS- in the brain helps us become awake, alert, and available to respond. NOTICE—salience helps something stand out because it is new, emotional, unexpected, rewarding, or potentially threatening. RELEVANCE—relevance helps the brain recognize how that information relates to our goals, needs, interests, or previous experiences. ATTENTION—directs our mental resources or a spotlight toward the selected information. ENCODE—begins forming a memory of what we are focused on. RETRIEVE AND REPEAT—strengthens the memory and makes it easier to access again. RECOVERY and CONSOLIDATION—so the brain and body can restore, and sleep can support memory consolidation. Leading us to-- INTEGRATION—to connect the new learning with what we already know. APPLY—Making the learning available and ready to use when we need it. So, in its expanded form, the Movement Loop looks like this: Movement → RAS-Supports Readiness → Salience and Relevance (what's important to us)→ Focused Attention → Encoding (forms the memory of what we are focused on)→ Retrieval and Repetition (to strengthen the neural pathway) → Recovery and Consolidation (important for the brain and body to be rested and recovered)→ Integration (connect new learning with what we already know)→ NEW Learning and Performance (ready and available for us whenever we need it). Here is an even easier way to remember how we LEARN: Move. Wake or Get Ready. Notice. Focus. Form a Memory. Strengthen it. Recover it. Connect it. Use it. Movement prepares the system. The RAS helps us become alert. Salience and relevance identify possible priorities. Attention selects the target. Encoding begins the memory. Retrieval and repetition strengthen it. Recovery and sleep help stabilize it. Integration connects it. And application makes it useful. These stages do not always occur in a perfectly straight line. We may notice something before we are fully focused on it. We may need several rounds of encoding and retrieval. We may sleep on an idea and understand it differently the following day. Or we may try to apply what we learned and discover that part of the pathway still needs strengthening. That is why this is a loop rather than a one-way process. Application produces feedback. That feedback shows us what we understand, what we can retrieve and use, and what still requires attention, repetition, or recovery. Then that feedback guides the next cycle of learning. We move again. We become ready. We direct our attention toward what matters. And with each cycle, we build learning that becomes more accessible, adaptable, and useful in our performance. PUT THIS INTO ACTION Before ending your next learning or work session, take one minute to ask: “What is the most important thing I want to remember?” Without looking at your notes, write down the central idea in your own words. Then decide when you will retrieve it again—perhaps later that day or the following morning. After that, give yourself permission to recover. When your attention is fading, another exhausted hour may not be as valuable as a break or a full night of sleep. The following day, try to retrieve the idea again before looking at your notes. Notice what remained accessible and what needs another repetition. Your experiment is simple: Summarize it. Sleep on it. Retrieve it again. Because learning begins while we are awake—but recovery and sleep help the brain continue the work. The Move–Focus–Learn Protocol BRINGING THE FIVE ACTIONS TOGETHER Here is the full Move–Focus–Learn experiment: Test this in school, work or personal learning: Use a brief walk or appropriate movement break before demanding cognitive work. This is what I told Dr. Medina 6 years ago is the only way I'm able to stay focused on writing difficult topics, like this one. Identify the one thing that deserves your attention next. Pick one priority you will focus on. Remove interference. Reduce unnecessary notifications, competing tasks and distractions. This can take a few minutes ahead of time, but keeps the learning slate clean so to speak. Create relevance. Ask, “Why does this matter to me—or to this learner?” Interact with the information you want to learn. Explain it, visualize it, discuss it, demonstrate it or apply it. Retrieve it. Close the book or screen and recall the important ideas without looking. Repeat it later. Return to the information after time has passed. Protect recovery. Allow sleep and recovery to support the next stage of learning. REVIEW AND CONCLUSION As we close out Episode 406, I want to return to the question we began with: Once movement activates and prepares the brain, what determines whether that readiness becomes lasting learning? The answer is not one single process. Learning emerges through a sequence of connected conditions: The brain and body must become ready. Something must stand out and feel relevant. Attention must select it. The information must be encoded. It must be retrieved and revisited. And recovery and sleep must provide opportunities for consolidation and integration. Dr. John Medina's Brain Rules helped us follow this sequence through five key lessons. LESSON 1: EXERCISE PREPARES THE BRAIN Movement helps create biological conditions that support alertness, attention, and cognition. The RAS contributes to this process by helping us become awake, alert, and ready to respond. But movement creates an opportunity—not a guarantee. A prepared brain still needs direction. LESSON 2: ATTENTION SELECTS WHAT MATTERS The brain encounters far more information than it can consciously process. Salience helps us notice what stands out. Relevance connects that information to our goals, needs, interests, or previous experiences. Attention then directs the brain's spotlight toward the selected target. Movement may create greater readiness, but attention determines where that readiness goes. LESSON 3: RETRIEVAL AND REPETITION STRENGTHEN WHAT ATTENTION BEGINS Paying attention once may create familiarity, but familiarity is not the same as learning. Encoding begins the memory. Retrieval asks the brain to locate that information again. Repetition gives us additional opportunities to strengthen our access to it. This is why explaining an idea without looking at our notes can be more useful than simply rereading it. Attention begins the pathway. Retrieval and repetition help make it last. LESSON 4: MEANINGFUL INTERACTION HELPS LEARNING STICK We can strengthen encoding by interacting with an idea in more than one meaningful way. We might see it, hear it, explain it, draw it, demonstrate it, or apply it. The goal is not to add as much stimulation as possible. The goal is to give the brain clear and relevant ways to understand, represent, and later retrieve the information. This is something I have experienced while creating this podcast. When I organize an idea into a framework or bring it to life in a visual graphic, I can see how the pieces connect. That helps me explain the idea more clearly, remember it more easily, and apply it more effectively. LESSON 5: RECOVERY ALLOWS LEARNING TO CONTINUE Learning does not necessarily end when we close the book, leave the classroom, finish the meeting, or stop practicing. During sleep, newly encoded information may be reactivated, stabilized, reorganized, and connected with existing knowledge. Deep non-REM sleep and REM sleep may contribute to this process in different but complementary ways. This is why recovery is not separate from learning. Recovery is part of the learning process. PUTTING THE MOVEMENT LOOP TOGETHER The complete cognitive side of the Movement Loop now looks like this: Movement prepares the brain and body. RAS-supported arousal helps us become awake and alert. Salience and relevance help identify possible priorities. Attention selects the target. Encoding begins the memory. Retrieval and repetition strengthen it. Recovery and sleep support consolidation. Integration connects the new learning with what we already know. And application makes that learning available when we need it. Or, in its simplest form: Move. Wake. Notice. Focus. Form. Strengthen. Recover. Connect. Use. Movement creates readiness. Attention provides direction. Encoding begins the memory. Retrieval and repetition strengthen the pathway. Recovery supports consolidation and integration. And application turns what we have learned into improved performance. Together, these processes help turn activity into lasting learning. FINAL THOUGHT This is not the first time we have explored Dr. John Medina's work, but each return has allowed us to ask a different question. In Episode 42[ix], we asked: How should schools and workplaces change when we understand the brain? In Episode 370[x], we asked: How can neuroscience and emotional regulation improve learning environments? In Episode 395[xi], we asked: What captures attention and motivates behavior? And here in Episode 406, we asked: How does an activated and attentive brain convert an experience into learning? That question has helped us add important detail to the Movement Loop. Movement alone does not create learning. Attention alone does not create lasting memory. Repetition without meaning may not produce understanding. And effort without recovery may not give the brain the conditions it needs to consolidate and integrate what happened. Each part of the process matters. Before we close, consider these questions: What are you preparing your brain to notice? Where is your attention going after you move? Are you interacting with important information deeply enough to encode it? Are you retrieving what you are learning—or merely rereading it? And are you protecting the recovery that allows learning to continue? Because what we repeatedly attend to, retrieve, and apply begins to shape what we know, what we can do, and how we perform. PREPARING FOR EPISODE 407 Movement can prepare the brain. Attention can direct it. Encoding can begin the memory. Retrieval and repetition can strengthen it. And recovery can help consolidate and integrate it. But every part of this process requires energy. The brain needs energy to direct attention, form memories, regulate behavior, and sustain performance. The body needs energy to move, adapt, recover, and begin the cycle again. So in Episode 407, we will revisit Jason Wittrock's work through a more current and carefully defined lens. We'll examine his experience with nutrition and fasting as an applied practitioner and personal case study, while comparing those ideas with current evidence surrounding nutrition, blood-sugar stability, metabolic flexibility, recovery, and performance. Because the brain and body cannot sustain performance without the energy required to power the system. I'll see you next time as we ask: How does metabolic health influence our capacity to move, learn, recover, and perform? RESOURCES Clip 1 with Dr. John Medina https://www.youtube.com/shorts/zDItOHAc8qQ Full Interview with Dr. John Medina https://www.youtube.com/watch?v=CFzg5nQnEMs REFERENCE   [i] John Medina's Brain Rule #4 https://brainrules.net/article/attention/   [ii] Neuroscience Meets Social and Emotional Learning Podcast EPISODE 42 with Dr. John Medina on “Implementing Brain Rules in Schools and Workplaces of the Future” https://andreasamadi.podbean.com/e/dr-john-medina-on-implementing-brain-rules-in-the-schools-and-workplaces-of-the-future/   [iii]Neuroscience Meets Social and Emotional Learning Podcast EPISODE 403 https://andreasamadi.podbean.com/e/movement-first-how-a-20%e2%80%91minute-walk-lights-up-the-brain/     [iv]Neuroscience Meets Social and Emotional Learning Podcast EPISODE 404 https://andreasamadi.podbean.com/e/movement-matters-how-every-move-rewires-the-brain/   [v] Neuroscience Meets Social and Emotional Learning Podcast EPISODE 405 https://andreasamadi.podbean.com/e/movement-isnt-enough-how-recovery-drives-real-adaptation/   [vi]Neuroscience Meets Social and Emotional Learning Podcast EPISODE 272 https://andreasamadi.podbean.com/e/brain-fact-friday-on-priming-the-reticular-activating-system-to-achieve-our-goals-in-2023/   [vii] Neuroscience Meets Social and Emotional Learning Podcast EPISODE 395 https://andreasamadi.podbean.com/e/theory-of-mind-the-missing-link-between-attention-reward-and-motivation/   [viii]Neuroscience Meets Social and Emotional Learning Podcast EPISODE 84  https://andreasamadi.podbean.com/e/how-a-spect-scan-can-change-your-life-part-3-with-andrea-samadi/   [ix] Neuroscience Meets Social and Emotional Learning Podcast EPISODE 42 with Dr. John Medina on “Implementing Brain Rules in Schools and Workplaces of the Future” https://andreasamadi.podbean.com/e/dr-john-medina-on-implementing-brain-rules-in-the-schools-and-workplaces-of-the-future/   [x]Neuroscience Meets Social and Emotional Learning Podcast EPISODE 370 https://andreasamadi.podbean.com/e/brain-rules-revisited-how-neuroscience-can-transform-classrooms/   [xi]Neuroscience Meets Social and Emotional Learning Podcast EPISODE 395 https://andreasamadi.podbean.com/e/theory-of-mind-the-missing-link-between-attention-reward-and-motivation/      

a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck's individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines. Stéphane explains how the treatment works by sequencing an individual patient's tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack. They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna's longer-term work applying mRNA to rare genetic and autoimmune diseases. Resources: Follow Stéphane Bancel on LinkedIn: https://www.linkedin.com/in/st%C3%A9phane-bancel-8185251/ Follow Jorge Conde on X: https://x.com/JorgeCondeBio Stay Updated:Find a16z on YouTube: YouTubeFind a16z on XFind a16z on LinkedInListen to the a16z Show on SpotifyListen to the a16z Show on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.